

1 **Amphiphilic peptide-tagged N-cadherin forms radial glial-like fibers that enhance**
2 **neuronal migration in injured brain and promote sensorimotor recovery**

3
4 Yuya Ohno^{a,b,1}, Chikako Nakajima^{a,1}, Itsuki Ajioka^{c,d}, Takahiro Muraoka^{d,e}, Atsuya
5 Yaguchi^e, Teppei Fujioka^b, Saori Akimoto^{c,d}, Misaki Matsuo^a, Ahmed Lotfy^f, Sayuri
6 Nakamura^a, Vicente Herranz-Pérez^g, José Manuel García-Verdugo^g, Noriyuki
7 Matsukawa^b, Naoko Kaneko^{a,h,*}, Kazunobu Sawamoto^{a,i,**}

8
9 ^a *Department of Developmental and Regenerative Neurobiology, Institute of Brain Science, Nagoya City University Graduate School*
10 *of Medical Sciences, Nagoya, Aichi 467-8601, Japan*

11 ^b *Department of Neurology and Neuroscience, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467-*
12 *8601, Japan*

13 ^c *Center for Brain Integration Research (CBIR), Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan*

14 ^d *Kanagawa Institute of Industrial Science and Technology (KISTEC), Kanagawa 243-0435, Japan*

15 ^e *Department of Applied Chemistry, Graduate School of Engineering, Tokyo University of Agriculture and Technology, Koganei,*
16 *Tokyo 184-8588, Japan*

17 ^f *Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University,*
18 *Beni-Suef, 62511, Egypt*

19 ^g *Laboratory of Comparative Neurobiology, Cavanilles Institute, University of Valencia, CIBERNED, 46980, Valencia, Spain*

20 ^h *Laboratory of Neuronal Regeneration, Graduate School of Brain Science, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan*

21 ⁱ *Division of Neural Development and Regeneration, National Institute of Physiological Sciences, Okazaki, Aichi 444-8585, Japan*

22
23 ¹ These authors contributed equally

24
25 * Corresponding author: Laboratory of Neuronal Regeneration, Graduate School of Brain Science, Doshisha University,
26 1-3 Tatara Miyakodani, Kyotanabe-shi, Kyoto 610-0394, Japan

27
28 ** Corresponding author: Department of Developmental and Regenerative Neurobiology, Institute of Brain Science,
29 Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi
30 467-8601, Japan

31
32 *E-mail addresses:* nkaneko@mail.doshisha.ac.jp (Naoko Kaneko), sawamoto@med.nagoya-cu.ac.jp (Kazunobu
33 Sawamoto)

34
35 **Running headline**

36 **N-cadherin-conjugated hydrogel promotes neuronal regeneration**

1 **Abstract**

2 The mammalian brain has very limited ability to regenerate lost neurons and recover
3 function after injury. Promoting the migration of young neurons (neuroblasts) derived
4 from endogenous neural stem cells using biomaterials is a new and promising approach
5 to aid recovery of the brain after injury. However, the delivery of sufficient neuroblasts
6 to distant injured sites is a major challenge because of the limited number of scaffold cells
7 that are available to guide neuroblast migration. To address this issue, we have developed
8 an amphiphilic peptide [(RADA)₃-(RADG)] (mRADA)-tagged N-cadherin extracellular
9 domain (Ncad-mRADA), which can remain in mRADA hydrogels and be injected into
10 deep brain tissue to facilitate neuroblast migration. Migrating neuroblasts directly
11 contacted the fiber-like Ncad-mRADA hydrogel and efficiently migrated toward an
12 injured site in the striatum, a deep brain area. Furthermore, application of Ncad-mRADA
13 to neonatal cortical brain injury efficiently promoted neuronal regeneration and functional
14 recovery. These results demonstrate that self-assembling Ncad-mRADA peptides mimic
15 both the function and structure of endogenous scaffold cells and provide a novel strategy
16 for regenerative therapy.

17

18 **Keywords**

19 Self-assembling peptide, injectable hydrogel, scaffold material, neuronal migration,
20 neuronal regeneration, ventricular-subventricular zone

21

1

2


3 **Highlights**

- 4 • A novel self-assembling Ncad-mRADA peptide forms a supramolecular hydrogel
- 5 • mRADA hydrogel incorporates the N-cadherin extracellular domain tagged with mRADA
- 6 • Ncad-mRADA hydrogel provides a scaffold for neuroblast migration in injured brain
- 7 • Migrating neuroblasts directly interact with radial-glia-like Ncad-mRADA fibers
- 8 • Ncad-mRADA promotes neuroblast migration and functional recovery after brain injury

9

10

11 **Graphical abstract**



12

13

14

1 **Introduction**

2 Brain injury, such as stroke, causes significant loss of neurons, leading to a
3 variety of irreversible neurological dysfunctions. To fundamentally treat brain injury, lost
4 neurons need to be regenerated, but no such treatment exists. Biomaterials, which are
5 biocompatible and biodegradable, show promise for promoting tissue repair. The use of
6 biomaterials to deliver various regeneration-promoting factors (e.g., growth factors) to
7 damaged tissues has recently been attempted for neuronal regeneration using neural stem
8 cells (NSCs) [1–4].

9
10 In the postnatal mammal brain, NSCs reside within the ventricular-
11 subventricular zone (V-SVZ) of the walls of the lateral ventricles, and have the ability to
12 generate immature neurons [5,6]. In the rodent brain, these immature neurons
13 (neuroblasts) form chain-like aggregates that enter the rostral migratory stream and
14 migrate toward the olfactory bulb [7,8]. Upon injury, neural stem cells are activated to
15 promote neuroblast production [9–11]. Neuroblasts are attracted by chemokines and
16 migrate toward lesion sites [6]. Similar to the normal physiological state, neuroblasts in
17 the injured brain utilize neighboring neuroblasts [12], blood vessels [12–15], and radial
18 glial cells [16] as scaffolds for their migration. However, neuroblast migration is inhibited
19 by reactive astrocytes hypertrophied by injury [17]. By promoting neuroblast migration,
20 regenerated neurons are localized in appropriate positions, facilitating functional repair
21 of the brain [17]. The use of neuroblasts derived from endogenous NSCs has the
22 advantage of reducing tumorigenic risk associated with cell transplantation [18–20] and
23 emerge as a safe and practical approach in regenerative medicine. Therefore, it is
24 necessary to develop artificial scaffold materials that mimic the function and structure of
25 the physiological scaffolds that facilitate the migration of endogenous neuroblasts.

26
27 We have previously reported that a porous sponge containing laminin, an
28 extracellular matrix component of the basement membrane of blood vessels, transplanted
29 into injured neonatal cortex promotes neuroblast migration [21]. We have also shown that
30 sponges containing the extracellular domain of N-cadherin, a homophilic intercellular
31 adhesion molecule expressed in radial glial cells and neuroblasts, promote the migration
32 of neuroblasts that can differentiate into mature neurons and contribute to functional
33 recovery [16]. While these studies indicate that sponges may be useful in the treatment of
34 cortical lesions, there are limitations to the introduction of such solid materials into deep
35 brain tissue, as their application is invasive and disrupts residual neuronal circuits.
36 Neuronal regeneration in the deep brain requires minimally invasive materials, such as
37 self-assembling peptides that form hydrogels when in contact with physiological fluids

1 [22–24]. We and other groups have reported that several injectable materials, such as
2 laminin-mixed amphiphilic peptides (RADA)₄ [13], self-assembling peptides containing
3 BDNF [25], and amphiphilic peptides incorporating Tenascin-C-mimetic short peptide
4 [26], promote neuroblast migration when injected into the adult brain. The development
5 of novel self-assembling peptides that form a hydrogel, characterized by a suitable
6 scaffold structure for cell migration and the ability to more stably incorporate cell
7 adhesion molecules, is needed to promote neuroblast migration in deep brain regions to
8 effectively promote functional recovery.

9
10 We previously generated an amphiphilic peptide [(RADA)₃-(RADG)] (here
11 referred to as mRADA) with reduced viscoelasticity compared with the original (RADA)₄
12 (here referred to as RADA) [27]. Here, we created a new material, the extracellular
13 domain of N-cadherin tagged with an mRADA (Ncad-mRADA) that stably associates
14 with mRADA hydrogels. The Ncad-mRADA-containing hydrogels promoted neuroblast
15 migration and improvement in sensorimotor functions in mouse models of brain injury.

16 17 **Materials and Methods**

18 19 **Animals**

20 Wild-type Institute of Cancer Research (ICR) mice and were purchased from
21 Japan SLC (Shizuoka, Japan). *Dcx-EGFP* mice [28] were obtained from the Mutant
22 Mouse Research Resource Center (MMRRC. RRID: MMRRC_000244-MU). *NSE-DTA*
23 transgenic mice [29] were obtained from S. Itohara. All experiments on live animals were
24 performed in accordance with the ARRIVE guidelines, the U.K. Animals (Scientific
25 Procedures) Act, 1986, the National Research Council's Guide for the Care and Use of
26 Laboratory Animals, and the guidelines and regulations of Nagoya City University.

27 28 **Peptide synthesis**

29 RADA (Ac-RADARADARADARADA-NH₂) and mRADA (Ac-
30 RADARADARADARADG-NH₂) were synthesized as previously reported [27]. For the
31 synthesis of mRADA with selenomethionine (Ac-RADARADARADARADGSem-NH₂),
32 Fmoc-Sem-OH was prepared by the following procedure. To an aqueous solution (5 mL)
33 of seleno-L-methionine (0.188 g, 0.959 mmol, Nacalai Tesque, Kyoto, Japan) and
34 NaHCO₃ (0.193 g, 2.30 mmol, Kishida Chemical, Tokyo, Japan) a 1,4-dioxane solution
35 (10 mL, Kishida Chemical, Tokyo, Japan) of Fmoc-OSu (0.344 g, 1.02 mmol, Watanabe
36 Chemical Industries, Hiroshima, Japan) was added dropwise over 90 min. After stirring

1 for 24 h at 25°C, 2 M HCl aq. was added to acidify the reaction mixture to pH 3. The
2 reaction mixture was extracted with EtOAc (10 mL, three times), and the collected
3 organic phase was washed with saturated NH₄Cl aq. (10 mL, once) and water (10 mL,
4 twice). The organic phase was dried with Na₂SO₄. After filtration to remove insoluble
5 substances, the organic phase was evaporated. The residue was separated on Sfär Silica
6 HC D High Capacity Duo 20 µm using Isolera flash column chromatography of Biotage
7 (Uppsala, Sweden) with a gradient elution between EtOAc and hexane (5/95 to 80/20) to
8 isolate Fmoc-Sem-OH (0.245 g, 0.585 mmol) with 61% yield. JEOL ECX-400 ¹H NMR
9 (400 MHz, CDCl₃) δ 8.19 (brs, 1H), 7.75 (d, *J* = 8.0 Hz, 2H), 7.61–7.50 (m, 2H), 7.39 (t,
10 *J* = 7.5 Hz, 2H), 7.30 (t, *J* = 7.5 Hz, 2H), 5.44 (d, *J* = 8.6 Hz, 1H), 4.56–4.49 (m, 1H),
11 4.43 (d, *J* = 6.9 Hz, 1H), 4.22 (t, *J* = 6.9 Hz, 1H), 2.61–2.50 (m, 1H), 2.48–2.36 (m, 1H),
12 2.31–2.20 (m, 1H), 2.13–2.01 (m, 1H), 1.99 (s, 2H), 1.93 (s, 1H) ppm, JEOL ECX-400
13 ¹³C NMR (125 MHz, CDCl₃) δ 176.69, 156.23, 143.87, 143.68, 141.43, 127.87, 127.19,
14 125.13, 120.14, 67.23, 53.94, 47.23, 32.75, 20.36, 4.36 ppm; Advion expression CMS-L
15 ESI MS (MeOH, positive mode): *m/z* 420.1 (monoisotopic mass of C₂₀H₂₂NO₄Se [*M* +
16 H]⁺: 420.07). mRADA with selenomethionine was synthesized following the same
17 synthetic protocol as RADA and characterized by Bruker autoflex speed matrix-assisted
18 laser desorption/ionization - time of flight mass spectrometry (2,5-dihydroxybenzoic acid,
19 reflector positive mode): *m/z* 1877.85 (monoisotopic mass of C₇₀H₁₂₁N₃₀O₂₆Se [*M* + H]⁺:
20 1877.82).

21 EGFP-mRADA and Ncad-mRADA were created as below. To generate *pCAG-*
22 *EGFP-6×Histag-A16G*, the *6×Histag-A16G* cDNA, attached *NotI* and *XhoI* sites were
23 generated by annealing the DNA oligos, 5'-GGCCCATCATCAT
24 CATCATCATCGAGCAGACGCCCGTGCGGATGCTAGAGCGGACGCCAGAGCA
25 GATGGTTA-3' and 5'-
26 TCGAGTTAACCATCTGCTCTGGCGTCCGCTCTAGCATCCGCACGGGCGTCTG
27 CTCGATGATGATGATGATGATG-3', followed by insertion into the *NotI/XhoI* sites of
28 *pCAG-EGFP-6×Histag* [30]. To generate a universal *pCAG-CST-6×Histag-A16G*
29 plasmid, from which desirable A16G-tagged proteins can be easily generated, the cDNA
30 encoding *6×Histag-A16G* was amplified from *pCAG-EGFP-6×Histag-A16G* using the
31 following primers 5'-AAGCGGCCGCCATCATCATCATCATCG-3' and 5'-
32 CAGCTATGACCATGATTACGCC-3' and then inserted into the *NotI* site of *pCAG-*
33 *CST-HA* [31]. To generate *pCAG-Ncad-Fc-6×Histag-A16G*, we amplified the cDNA
34 encoding *Ncad-Fc-6×Histag* from *pRc/CMV-Ncad-Fc* [32] using the following primers
35 5'-AAGCTAGCCATGTGCCGGATAGCGGGAG-3' and 5'-
36 AACTCGAGTTAATGATGATGATGATGATGTCTAGATTTACCAGGAGAGTG
37 GAGA-3'. Then the amplicon was inserted into the *NotI/XhoI* sites of *pCAG-CST-*

1 *6×Histag-A16G*. To generate *pCAG-Ncad-6×Histag-A16G*, we obtained the cDNA
2 encoding the *Ncad* by *NheI/NotI* digestion and inserted it into *pCAG-CST-6×Histag-*
3 *A16G*.

4 To obtain genetically engineered proteins, 293T cells (5.2×10^5 cells) were
5 plated in 6-well plates in 2.5 mL Dulbecco's modified Eagle's medium containing 10%
6 fetal bovine serum (FBS). One day later, the cells were transiently transfected with *pCAG-*
7 *EGFP-6×Histag*, *pCAG-EGFP-6×Histag-A16G*, or *pCAG-Ncad-6×Histag-A16G* using
8 TransIT-LT1 Transfection Reagent according to the manufacturer's instructions. To
9 obtain Ncad-mRADA, the conditioned medium was collected at 7 days after transfection,
10 passed through a 0.45- μ m filter, concentrated using an ultrafiltration column (Amicon
11 Ultra 10K; Merck, Darmstadt, Germany), displaced in phosphate buffer (PB, pH 7.4), and
12 kept at -80°C before use. To obtain EGFP-mRADA and non-tagged EGFP, transfected
13 293T cells were lysed in lysis buffer [20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM
14 ethylene-diamine-tetra-acetic acid (EDTA), 1% NP-40, and protease inhibitor (Complete
15 EDTA-free)], and the samples were centrifuged at $15,000 \times g$ for 5 min. The soluble
16 fraction was concentrated using an ultrafiltration column (Amicon Ultra 10K, Merck),
17 displaced in PB (pH 7.4), and kept at -80°C before use. These proteins were characterized
18 by western blotting analysis (Fig. S1A).

19 20 **Peptide solution preparation**

21 The synthesized peptide solution was prepared freshly before use as follows. Stock
22 solutions of RADA and mRADA (1 v/v%) were diluted to 0.5 v/v% with autoclaved
23 distilled water. Stock solutions of Ncad-mRADA and Ncad-Fc, which both contain 80
24 ng/ μ L N-cadherin, were diluted 50% by adding 1 v/v% mRADA stock solution. These
25 peptide solutions were adjusted to neutral pH before use by PBS. We named the hydrogel
26 formed from the mixture of Ncad-mRADA and mRADA peptide solution as "Ncad-
27 mRADA hydrogel", and that from the mRADA peptide solution containing Ncad-Fc
28 protein as "Ncad hydrogel". Selenomethionine-labeled mRADA stock solution (1 v/v%)
29 was either diluted with autoclaved distilled water or with Ncad-mRADA stock solution
30 to make 0.5 v/v% solutions.

31 32 **Incorporation and release assay**

33 Incorporation of EGFP, EGFP-mRADA, Ncad-Fc and Ncad-mRADA into the
34 mRADA hydrogels was evaluated as follows. Fifty microliters of 2% mRADA solution
35 at pH 3 was mixed with 50 μ L of EGFP, EGFP-mRADA, Ncad-Fc or Ncad-mRADA (50
36 ng) in PB (pH 7.4). After incubation at 37°C in a CO_2 incubator for 24 hours (h), the
37 hydrogels were washed with 250 μ L phosphate buffered saline (PBS) (pH 7.4). The

1 concentration of EGFP and EGFP-mRADA in the soluble fraction was measured by
2 ELISA. EGFP and EGFP-mRADA incorporation were calculated using the following
3 formula. Protein incorporation (%) = [(weight of input) – (weight of the soluble fraction)]
4 / (weight of input) × 100 (%). mRADA hydrogels incorporated with EGFP-mRADA as
5 described above were washed with PBS three times and incubated with 200 µL 10% FBS
6 in PBS at 37°C and at 500 rpm (CM-1000; EYELA, Tokyo, Japan). After 6, 12, 24, 72,
7 96, 168, and 336 h, the soluble fractions were collected and then incubated with 200 µL
8 10% FBS in PBS. EGFP-mRADA release was calculated using the following formula.
9 Unreleased protein / incorporated protein (%) = [(weight of incorporated protein) – (total
10 weight of the soluble fraction)] / (weight of incorporated protein) × 100 (%).
11 Incorporation and sustained-release assays were performed two times independently and
12 evaluated. The incorporation and release of Ncad-Fc and Ncad-mRADA were evaluated
13 by western blot analysis. The soluble fraction samples after incorporation, PBS-washing,
14 and 144 h-incubation were concentrated using an ultrafiltration column (Amicon Ultra
15 10K, Merck). The collected samples were mixed with sodium dodecyl sulfate loading
16 buffer and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on
17 7.5% polyacrylamide gels. The proteins were then electroblotted onto polyvinylidene
18 fluoride membranes using an iBlot Gel Transfer Device (Thermo Fisher Scientific). The
19 membranes were blocked with 5% skimmed milk for 1 h at room temperature, incubated
20 with a rabbit anti-N-cadherin antibody (1:5,000, ab76011; Abcam) for 16 h at 4°C, and
21 then incubated with a peroxidase-labeled goat anti-rabbit IgG (1:5,000, Dako, Glostrup,
22 Denmark) for 2 h. The bands were detected using SuperSignal West Femto Maximum
23 Sensitivity Substrate (Thermo Fisher Scientific) and visualized using a Sayaca-Imager
24 (DRC; Tokyo, Japan).

25

26 **V-SVZ-derived neuroblast culture**

27 Glass-bottom 35-mm Petri dishes coated with the mRADA, Ncad, or Ncad-
28 mRADA hydrogels were prepared prior to cell preparation. The dishes were incubated
29 with the biomaterial solution for 30 min at 4°C and for a further 30 min at 37°C. The
30 dishes were rinsed once with PBS (pH 7.4) and air-dried in a laminar flow hood until use.

31 V-SVZ tissues were dissected from postnatal day 0 (P0)–P1 ICR mice. Pooled
32 tissues were dissociated with trypsin-EDTA (Thermo Fisher Scientific). The cells were
33 washed with L-15 medium (Thermo Fisher Scientific) containing 20 µg/ml DNaseI
34 (Roche). The cell aggregates were embedded in 50% Matrigel (BD Biosciences) and
35 diluted in Hank's balanced salt solution (Thermo Fisher Scientific). The cells were
36 cultured in Neurobasal medium containing 2% B-27 supplement, 2 mM L-glutamine and

1 50 U/ml penicillin-streptomycin at 37°C with 5% CO₂ for 48 h before imaging. Details
2 of the cell preparation are described elsewhere [33].

3 Time-lapse video recordings were performed using a BZ-X800 fluorescence
4 microscope (Keyence, Osaka, Japan) equipped with a ×20 dry objective lens. Images
5 were obtained every 1 or 5 min for 24 h under humidified conditions at 37°C with 5%
6 CO₂. The migrating neuroblasts identified by their small mono/bipolar morphology and
7 saltatory movement were analyzed using a manual tracking plugin of the ImageJ software
8 (National Institutes of Health, Bethesda, MD, USA). The resting phase was defined as a
9 migration speed slower than 0.1 μm/min.

11 **Ischemic stroke**

12 Cerebral stroke was induced in 12–16-week-old male mice. Mice were deeply
13 anesthetized by spontaneous inhalation of 1–2% isoflurane in oxygen and placed on a
14 37°C heated bed (model BMT-100, Bio Research Center, Nagoya, Japan). Middle
15 cerebral artery occlusion (MCAO) was induced by the intraluminal filament technique,
16 as reported previously [34] with several modifications. In brief, after occlusion of the
17 common carotid artery, the right carotid bifurcation was exposed, and the external carotid
18 artery was coagulated distal to the bifurcation. A 10.0-mm silicone-coated 8-0 filament
19 was then inserted through the stump of the external cerebral artery and gently advanced
20 to occlude the middle cerebral artery, and the incision was closed. The mice were re-
21 anesthetized 40 min later, the incision was re-opened, and the filament was gently
22 withdrawn. The incision was then closed again. After this procedure, mice were returned
23 to their home cage. Since the extent of stroke-induced neuroblast migration is strongly
24 correlated with the infarct size, we only used individuals with strong GFAP signal
25 covering 10-25% of the ipsilateral hemisphere for analysis of post-MCAO samples.

26 The animals were ranked according to their body weight loss during the first one
27 week after MCAO, and then successively assigned to treatment groups so that the mean
28 body weight loss in each group was about the same.

29 In sham operation, under deep anesthesia, right common carotid artery was
30 exposed, but not occluded, and then the incision was closed.

32 **Cryogenic brain injury**

33 Cortical cryogenic injury was performed on postnatal day 2 (P2) mice or 10–16-
34 week-old male mice as described previously [16,21]. Mice were placed in a stereotaxic
35 instrument (David Kopf Instruments, US) and anesthetized with 1% isoflurane in oxygen
36 (0.3 L/min) and the skull was exposed through a scalp incision. A pre-chilled hexagonal
37 wrench was prepared in liquid nitrogen; a 1.2 mm-wide and a 3.0 mm-wide wrench for

1 neonatal and adult mice, respectively. The metal probe was placed on the exposed right
2 skull (0.5-mm anterior and 1.2-mm lateral to lambda for P2 mice and 0.5-mm anterior
3 and 1.2-mm lateral to bregma for adult mice) for 10 seconds. For neonatal mice, the
4 procedure was repeated three times with a time interval of 5 seconds to re-chill the probe,
5 while the procedure was repeated 12 times for adult mice. The scalp was sutured and the
6 mice were placed in a heated recovery box for 15 min, and then returned to their home
7 cage.

9 **Injection of self-assembling peptides**

10 Mice were deeply anesthetized by spontaneous inhalation of 1–3% isoflurane.
11 Prior to injection of the self-assembling peptides, the scalp and parietal bone near the
12 injection sites were resected to expose the brain. The peptide solution was loaded into a
13 glass capillary needle and slowly stereotaxically injected into either intact or injured
14 brains as follows. Adult 8–10-week-old male mice were used for intact mice injection
15 experiments. 2.5 μ l of the peptide solution was injected into the right and left medial
16 striata (coordinates: 1.3 mm anterior, 1.3 mm lateral to bregma, 2.0–2.6 mm deep).
17 Injection of 3 μ l peptide solution throughout the striatum from the lateral wall of the
18 lateral ventricle of intact adult or 13 \pm 1 day-post-MCAO mice was performed by tilting
19 the head to an angle of 45° (coordinates: 1.55 mm anterior, 0.8 mm lateral to bregma,
20 1.5–3.0 mm deep). Intracortical injection was performed on 2-day-post-cryoinjured mice
21 and 2.5 μ l peptide solution was slowly injected into the lesion site (coordinates: 0.5 mm
22 anterior, 0.95 mm lateral to bregma, 1.4–2.2 mm deep from the skull surface). Neonatal
23 4-day-post-cryoinjured mice were subjected to intracortical injection of 2 μ l peptide
24 solution into the lesion site (1.0–1.5 mm deep from the skull surface). After the injection,
25 the capillary needle was kept in the injection site for 5–7 min, until hydrogel formation
26 was accomplished. Mice were transcardially perfused 5 or 25 days after the injection with
27 PBS (pH 7.4), followed by 4% paraformaldehyde (PFA) in 0.1 M PB (pH 7.4). Tissues
28 were further fixed in the same fixative overnight.

30 **Postnatal V-SVZ electroporation**

31 Neonatal ICR or *NSE-DTA* pups (P0–1) were anesthetized by hypothermia (1
32 min) and fixed in a stereotaxic instrument. A pulled glass capillary needle was loaded
33 with 2 μ l plasmid solution (4 μ g/ml *pCAGGS-EmGFP* [35] in distilled water containing
34 0.01% Fast Green). The capillary needle was placed into the lateral ventricle of the right
35 hemisphere (2.0 mm anterior, 1.2 mm lateral to lambda and 2.0 mm deep) and the plasmid
36 was injected. The animals were subjected to three electrical pulses (70 V, 20.0 msec)
37 using a Super Electroporator NEPA21 Type II (Nepa Gene, Chiba, Japan) and 10 mm

1 tweezer electrodes (CUY650P10, Nepa Gene, Chiba, Japan). Electroporated animals
2 were placed on a heating plate before being returned to their home cage.

3 4 **Immunohistochemistry**

5 Brain sections were prepared and stained as previously described [13]. Briefly,
6 50 or 60- μ m-thick coronal sections were prepared with a vibratome VT1200S (Leica,
7 Wetzlar, Germany). The sections were incubated in blocking solution (10% normal
8 donkey serum, 0.4% Triton X-100 in PBS) for 60 min at room temperature, then in
9 primary antibody solution overnight at 4°C, followed by secondary antibody solution
10 containing AlexaFluor-conjugated secondary antibodies (1:1,000, Thermo Fisher
11 Scientific) for 2 h at room temperature. Signals were amplified with biotinylated
12 secondary antibodies (1:500, Jackson Laboratory, West Grove, PA, USA) and the
13 Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA), and visualized
14 using the TSA Fluorescence System (Akoya Biosciences, Marlborough, MA, USA). The
15 Click reaction was used to visualize the alkyne-modified RADA and mRADA hydrogels
16 by incubating sections in Click reaction solution [100 mM Tris-HCl (pH 8.0), 15 mM
17 CuSO₄, 0.5 mM Tris (3-hydroxypropyltriazolylmethyl) amine (Tokyo Chemical Industry
18 Co., Ltd.), 200 mM ascorbic acid, AlexaFluor 647-conjugated azide (Alexa647-azide,
19 1:50, Thermo Fisher Scientific)] for 30 min at room temperature. For CD31 staining,
20 sections were pretreated with 1% H₂O₂ for 40 min before blocking. The following
21 primary antibodies were used: goat anti-Iba1 (1:1,000, Abcam), rabbit anti-Iba1 (1:2,000,
22 Wako Pure Chemical Industries, Osaka, Japan), guinea-pig anti-DCX (1:800, Millipore),
23 rabbit anti-DCX (1:500, Cell Signaling Technologies), mouse anti-S100 β (1:200, Sigma-
24 Aldrich, St. Louis, MO, USA), rabbit anti-GFAP (1:1,000, DAKO), chicken anti-GFAP
25 (1:10,000, Abcam), rat anti-CD31 (1:100, BD Biosciences), rat anti-GFP (1:500, Nacalai,
26 Kyoto, Japan), rabbit anti-GFP (1:500, MBL, Tokyo, Japan), mouse anti-MAP2 (1:500,
27 Sigma Aldrich), rabbit anti-GAD67 (1:500, Millipore), mouse anti-Gephyrin (1:1,000,
28 Synaptic Systems), rabbit anti-NeuN (1:1,000, Abcam), and mouse anti-NeuN (1:200,
29 Millipore). Cell nuclei were stained with Hoechst 33342 stain (1:5,000, Invitrogen). For
30 quantification, coronal sections including the V-SVZ were used. To visualize the area
31 positive for immunostaining and to count cells, confocal z-stack images were captured
32 using an LSM700 confocal laser microscope (Carl Zeiss, Jena, TH, Germany) equipped
33 with 10 \times /0.45, 20 \times /0.8 and 40 \times /1.2 objective lenses, or an Olympus FV3000 confocal
34 microscope (Evident, Tokyo, Japan) equipped with 10 \times /0.4, 20 \times /0.8 and 40 \times /1.4
35 objective lenses. To measure GFAP⁺ area, z-stack images were captured using a BZ-
36 X810 fluorescence microscope (Keyence, Osaka, Japan) with a 20 \times /0.75 objective lens.
37 ImageJ (National Institutes of Health, Bethesda, MD, USA), Zen (Carl Zeiss, Jena,

1 Germany) and cellSens (Evident, Tokyo, Japan) were used for measurement. The images
2 of spines and neurites were captured using LSM880 confocal laser microscope (Carl Zeiss,
3 Jena, TH, Germany) equipped with Airyscan FAST (Carl Zeiss) in super-resolution mode
4 with a water-immersion 40×/1.2 (zoom 1.8) or oil-immersion 63×/1.4 (zoom 3.0)
5 objective lens. The gamma value was adjusted by Imaris (Bitplane, Oxford, United
6 Kingdom) to obtain images (Fig. 2C”, D”).

7 8 **Histological analyses**

9 Histological analyses of coronal sections were performed as follows. For the
10 analysis of Iba1+ microglial cells in the intact adult brain, sections were immunostained
11 for Iba1 and the hydrogel was visualized with Alexa647-azide. A single section
12 containing hydrogel in the striatum was selected from each animal. The Iba1+ area was
13 analyzed using ImageJ (National Institutes of Health, Bethesda, MD, USA). For analysis
14 of Dcx+ neuroblasts in the intact adult brain, sections containing hydrogel were selected.
15 The number of Dcx+ cells in every third section was counted and the number multiplied
16 by three to obtain the total number of Dcx+ cells per brain.

17 The number of Dcx+ neuroblasts in the ipsilateral striatum of post-MCAO
18 samples was obtained from sequential sections containing the hydrogels. To
19 quantitatively analyze GFAP and CD31 expression in MCAO brains, sections were
20 imaged for GFAP+ or CD31+ cells and the area within 100 μm from the injection site
21 was analyzed. The area within 100 μm from the V-SVZ was excluded from the analysis.

22 Dcx+ neuroblasts in the cortex were quantified in adult cryoinjured brain slices.
23 To visualize and quantitatively analyze Dcx+ cells, confocal z-stack images were
24 captured. The sections with injected hydrogels on the dorsal wall of the lateral ventricle
25 were selected for further analysis. The number of Dcx+ neuroblasts in every sixth section
26 was counted and the neuroblast number was multiplied by six to obtain the total number
27 of cells per brain.

28 Dcx+ neuroblasts were quantified in neonatal cryoinjured brain slices. To
29 visualize and quantitatively analyze Dcx+ cells in and around the hydrogels, confocal z-
30 stack images with a step size of 2 μm were captured. The number of Dcx+ cells in every
31 sixth section was counted and the hydrogel or lesion site area was measured to obtain the
32 density of Dcx+ cells.

33 The number of regenerated neurons in ICR mice was counted in all coronal
34 sections containing the injection and lesion track. The sections were co-stained for NeuN
35 and GFP to visualize mature neurons and V-SVZ-derived cells. The number of
36 NeuN+GFP+ co-expressing cells was counted from every second coronal sections for
37 *NSE-DTA* mice experiments and the cell number was multiplied by two to obtain the total

1 number of cells per brain. The numbers of NeuN- and GFP-immunoreactive cells were
2 counted under an optical microscope (Olympus BX-51, Evident, Tokyo, Japan) with a
3 20× objective lens.

4 5 **Transmission electron microscopy**

6 Adult wild-type mice five days after RADA or mRADA injection and
7 cryoinjured neonatal *Dcx-EGFP* mice four days after selenomethionine-labeled Ncad-
8 mRADA injection were fixed at P9 by transcardiac perfusion with 2% PFA and 2.5%
9 glutaraldehyde containing 0.1 M PB. The brain was extracted and post-fixed for 48 h in
10 the same fixative at 4°C and sliced into 200 μm coronal sections using a vibratome
11 (VT1200S, Leica). Appropriate sections, including the center of injury, injected
12 biomaterials, and migrating neuroblasts in the neocortex were selected for further
13 processing from cryoinjured brains based on images of EGFP fluorescence. The selected
14 sections were treated with 4% OsO₄ in 0.1 M PB for 90 min, dehydrated in graded
15 concentrations of ethanol and propylene oxide and embedded in epoxy resin (Durcupan,
16 Sigma Aldrich) for 72 h in a 60°C oven to complete polymerization of the resin. Serial
17 semi-thin sections (1.5-μm-thick) were cut with an ultramicrotome (UC7, Leica) using a
18 diamond knife (Histo, Diatome, Hatfield, PA, USA), and stained lightly with 1%
19 toluidine blue. After acquisition of the images with a transmitted light microscope
20 (Olympus BX51, Evident, Tokyo, Japan), the semi-thin sections were glued to Durcupan
21 blocks and detached from the glass slide by repeated freezing in liquid nitrogen and
22 thawing. Ultra-thin sections (60–70-nm-thick) were prepared from the semi-thin sections
23 using an ultramicrotome (UC7, Leica) and a diamond knife (SYM2045, Syntek,
24 Kanagawa, Japan), and stained with 2% uranyl acetate for 15 min and with modified
25 Sato's lead solution (Reynolds' solution) for 5 min. Images were captured using a
26 transmission electron microscope (JEM-1400Plus, JEOL, Tokyo, Japan) equipped with a
27 digital camera.

28 29 **Deletion of V-SVZ-derived cells differentiating into neuronal lineage cells**

30 P0 *NSE-DTA* mice [29,36] or C57BL/6J mice were anesthetized by brief
31 hypothermia and electroporated with the EmGFP encoding plasmid as described above.
32 On the next day (at P1), 1 μl solution of adenovirus encoding Cre recombinase under the
33 control of the cytomegalovirus promoter Ad-CMV-iCre (Vector Biolabs, Cat. 1045) was
34 stereotaxically injected into the right lateral ventricle (2.0 mm anterior, 1.2 mm lateral to
35 lambda and 2.0 mm deep). These mice were subjected to cryogenic cortical injury at P2,
36 followed by Ncad-mRADA injection into the injured sites at P5. Histological analyses
37 were performed using brain tissues fixed at P30 after the foot-fault test (see below).

2 **Neurological assessments**

3 Mice were subjected to quantitative neurological testing from P29-35. The body
4 weight was not statistically different among experimental groups.

5 **Foot-fault test:** The foot-fault test was performed on cryo-injured mice as previously
6 described with modifications [37]. Briefly, mice roamed on 20-cm elevated hexagonal
7 wire grids with 40-mm diameter openings for 10 min on a day prior to the test. During
8 the test, each mouse was tested for 5 min on the grid and the total number of steps and
9 foot-faults for the left hindlimb were recorded. A misplaced limb that slipped on the grid
10 or fell through the openings in the grid was counted as a foot-fault. The number of foot-
11 faults for the left hindlimb was divided by the total number of hindlimb steps to determine
12 percentage of the fault steps. The test was repeated twice on the same day for each mouse
13 and the fault rate averaged.

14 **Automatic gait analysis:** Gait analysis was performed using the Noldus CatWalk XT
15 (Noldus Information Technology, Wageningen, the Netherlands), an automated gait
16 analysis system, according to the manufacturer's instructions. Briefly, in a dark
17 environment, the mice were allowed to walk across a glass walkway illuminated with a
18 green light that was completely reflected internally except at the points receiving pressure.
19 The contact point of each paw on the glass was illuminated, which was recorded with a
20 high-speed video camera. The footprints recorded during each trial were analyzed using
21 the CatWalk XT 10.5 software to generate a series of parameters. At least three successful
22 sustained walk recordings for each mouse were used for each analysis, and the average
23 of the runs was reported. Among the multiple parameters, maximum contact area, the paw
24 area at the moment of maximum floor contact with the plate during a stance phase, was
25 compared among the experimental groups, as reported previously [16]. Since the paw
26 contact area was strongly correlated with the body weight, only the mice with average
27 body weight (mean \pm 2-fold standard deviation) were used for this experiment.

29 **Statistical analysis**

30 All data were analyzed using BellCurve for Excel (SSRI, Japan) and GraphPad
31 Prism 9 (GraphPad Software, USA). At least three independent experiments were
32 performed for each analysis. Data are expressed as the mean \pm standard error of the mean
33 (SEM) or as box and whisker plots with individual data points (in detail: median, upper
34 box bound (75%), lower box bound (25%), minus whisker, plus whisker). The Shapiro-
35 Wilk test (p value <0.01) or Bartlett's test (p value <0.01) and the F-test (p value <0.01)
36 were performed prior to the following tests. Comparisons between two groups were
37 performed with Student's t -test, Welch's t -test or the Wilcoxon rank sum test. When three

1 or more groups were compared, we applied the one-way ANOVA followed by the
2 Bonferroni post hoc test or the Kruskal-Wallis test followed by the Steel-Dwass test. The
3 one-way ANOVA test with a two-stage step-up method of Benjamini, Krieger and
4 Yekutieli [38,39] was used to correct for multiple comparisons by controlling the False
5 Discovery Rate in the behavioral tests. A p value < 0.05 and a q value < 0.05 were
6 considered statistically significant.

1 Results

3 Ncad-mRADA stably incorporates in mRADA supramolecular hydrogel

4 We previously developed mRADA, which has reduced viscoelasticity compared
5 with the original RADA [27]; however, the interaction of mRADA with the surrounding
6 tissue after injection into the brain has not been investigated. Among the previously
7 reported glycine substitution form of the RADA peptides, [(RADG)-(RADA)₃] also
8 showed lower viscoelasticity as mRADA [(RADA)₃-(RADG)]. In this study, we used
9 mRADA because [(RADG)-(RADA)₃] formed relatively shorter and fragmented fibrils,
10 mostly with 100-nm lengths, than mRADA that formed well-developed μm-long
11 nanofibers, which are expected to incorporate peptide-tagged protein more effectively.
12 We injected self-assembling mRADA and RADA peptides into the striatum of adult mice,
13 and then fixed five days later. The brains were sliced, and embedded into resin to prepare
14 semi-thin (1.5 μm-thick) sections. Staining of sections with toluidine blue and light
15 microscopy observation revealed that RADA formed large aggregates sharply demarcated
16 from the parenchyma, in which only a few cells were observed (Fig. 1A–A’). In contrast,
17 the boundary between the brain parenchyma and the mRADA hydrogel was irregular and
18 unclear, and many cells were distributed in these areas (Fig. 1B–B’). We then
19 investigated the precise distribution of the hydrogels in brain parenchyma using
20 transmission electron microscopy. While RADA hydrogel was only observed along the
21 injection scars (Fig. 1C–C’), thin aggregates of mRADA hydrogel with various
22 morphologies were widely distributed in and around the injection scars (Fig. 1D–D’).
23 Some of the mRADA fibers were connected with blood vessels or resident neurons or
24 glial cells, indicating that a single injection of mRADA peptides can provide a scaffold
25 for cell migration to a wide area of the brain.

26 We recently found that RADA-tagged EGFP (EGFP-RADA) was efficiently
27 incorporated into RADA hydrogels and more than 90% of the incorporated EGFP-RADA
28 remained in the RADA hydrogel after 168 h [30]. Here, we generated mRADA-tagged
29 EGFP (EGFP-mRADA) and examined its incorporation and release from mRADA
30 hydrogel. As expected, there was a difference in incorporation efficiency between EGFP-
31 mRADA and non-tagged EGFP: EGFP-mRADA was incorporated at 66 mol%, while the
32 incorporation of non-tagged EGFP was limited to 17 mol% (Fig. 1E). In a time-course
33 EGFP release assay, 96 mol% of EGFP-mRADA remained in mRADA hydrogel after
34 incubation for 336 h (Fig. 1F).

35 Using the mRADA expressing plasmid, we constructed a plasmid vector encoding
36 mRADA tagged with N-cadherin extracellular domain. HEK293T cells were transfected
37 with the plasmids to obtain Ncad-mRADA protein. In the presence of an excess amount

1 of mRADA peptides and in physiological pH and ionic conditions, such as those in brain
2 tissue and used in tissue culture, the Ncad-mRADA protein self-assembled and formed
3 an Ncad-mRADA supramolecular hydrogel (Fig. 1G). The rheological measurement
4 analysis indicated that Ncad-incorporation into the mRADA did not influence the
5 hydrogelation property of mRADA (Fig. S1B-C). As with EGFP-mRADA, Ncad-
6 mRADA was efficiently incorporated into an mRADA hydrogel and remained after
7 incubation for 144 h (Fig. 1H). In contrast, although Ncad-Fc (Fc-tagged Ncad) was
8 efficiently incorporated into mRADA hydrogel, Ncad-Fc was released when incubated
9 for 144 h (Fig. 1I). These results indicate that Ncad-mRADA was stably assembled with
10 mRADA hydrogel, while Ncad-Fc was not.

11 We have previously reported that an Ncad-Fc-conjugated gelatin sponge-like
12 biomaterial promotes neuroblast migration into the injured neocortex of neonatal mice
13 [16]. However, the sponge could not be transplanted beyond the corpus callosum
14 (hereinafter referred to as the CC) into deeper areas of the brain such as the striatum. In
15 contrast, the RADA, mRADA and Ncad-mRADA peptide solutions could be easily
16 injected into the striatum. In addition, the Ncad-mRADA peptide solution injected into
17 the adult mouse striatum formed loose hydrogel aggregates that intermingled well with
18 the surrounding tissue, similarly to mRADA (data not shown). To evaluate the
19 immunological response to these hydrogels, brain sections were immunostained for Iba1
20 (a marker for microglia) five days after injection of RADA, mRADA, or Ncad-mRADA
21 solution into the striatum (Fig. 1J). The hydrogel aggregates were visualized by a
22 chemical reaction with Alexa647-azide. Activated microglia with swollen ramified or
23 amoeboid-like cell bodies were accumulated close to, but not within, the hydrogel
24 aggregates. The percentage of Iba1+ area within 300 μ m of the hydrogel in the striatum
25 was not significantly different among the groups (Fig. 1K). Microglia in other brain
26 regions did not show activated morphology. These observations indicate that Ncad-
27 mRADA hydrogel disperses into the parenchyma and forms a histocompatible hydrogel
28 with a high cellular affinity comparable to mRADA, and with a focal and limited immune
29 response at the same level as that of RADA and mRADA.

30

31 **Ncad-mRADA induces ectopic migration of neuroblasts**

32 To analyze the ability of Ncad-mRADA hydrogel to act as a scaffold to support
33 migration of V-SVZ neuroblasts *in vivo*, the self-assembling peptides or PBS were
34 injected at an angle of 45 degrees to the cortex through the striatum to the V-SVZ (Fig.
35 S2A). Five days later, the coronal brain sections were prepared and immunostained for
36 Dcx (a marker for neuroblasts) (Fig. S2B). In the PBS group, almost all V-SVZ-derived
37 neuroblasts migrated toward the olfactory bulb, not the striatum (data not shown), as is

1 seen under normal physiological conditions [40]. In contrast, neuroblasts were observed
2 along the Ncad-mRADA hydrogel formed in the striatum (Fig. S2B). The numbers of
3 Dcx⁺ neuroblasts distributed that were closer than 300 μ m of the injection track were
4 counted. The number of neuroblasts along the material in the striatum was significantly
5 higher in the Ncad-mRADA group compared with that in the RADA or mRADA groups
6 (Fig. S2C), indicating that the Ncad-mRADA hydrogel provided an efficient scaffold
7 for neuroblasts to ectopically migrate into the brain parenchyma.

9 **Ncad-mRADA promotes neuroblast migration towards injured adult striatum**

10 After stroke, neuroblasts produced in the V-SVZ migrate toward the damaged area
11 [12,41,42]. We examined whether Ncad-mRADA hydrogel promotes the post-stroke
12 neuroblast migration using mice subjected to transient MCAO, which mainly produces
13 infarcts in the lateral striatum. Since stroke-induced neuroblast migration is strongly
14 correlated with the infarct size, we used only animals with moderate infarction (about 10-
15 25% of the area of a hemisphere), which weakly induces neuroblast migration from the
16 V-SVZ without interventions. Thirteen days after MCAO, the mice were injected with
17 mRADA or Ncad-mRADA peptides or PBS from the V-SVZ to the lateral striatum at a
18 45° angle (Fig 2A–B). Five days later, coronal brain sections were prepared and
19 immunostained for Dcx (Fig. 2C–D’), GFAP (a marker for astrocytes) (Fig. 2I, J), CD31
20 (a marker for vascular endothelial cells) (Fig. 2K, L) or Iba1 (Fig. 2M, N). We counted
21 the number of neuroblasts in the V-SVZ (Fig. 2E), and in the striatum that were closer
22 than 300 μ m to the injection trajectory (Fig. 2F). There was no significant difference in
23 the number of neuroblasts in the V-SVZ between the two groups (Fig. 2E). In the PBS
24 treated group, very few neuroblasts were observed in the post-stroke striatum along the
25 injection trajectory. mRADA injection slightly but significantly increased the number of
26 Dcx⁺ neuroblasts individually distributed along the hydrogel compared with the PBS
27 group (Fig. 2C, C’, C’). In contrast, much more neuroblasts were distributed in and
28 around the Ncad-mRADA hydrogel, some of which formed chain-like clusters (Fig. 2D,
29 D’, D’). The number of neuroblasts in the post-stroke striatum was significantly higher
30 in the Ncad-mRADA group compared with that in the mRADA group or PBS group at
31 all distances from the V-SVZ analyzed (Fig 2F). The majority of these neuroblasts were
32 distributed inside or near (< 200 μ m) the Ncad-mRADA scaffold (Fig. 2F).

33 Astrocytes and blood vessels were also observed in and around the biomaterials in
34 both groups at 18 days after MCAO (Fig. 2I–L). A comparison of their distribution in the
35 area within 100 μ m from the injection trajectory showed that the GFAP⁺ area percentage
36 and the total CD31⁺ vessel length were not significantly different between the groups
37 (Fig. 2G–H). Microglia were accumulated around but did not intrude into the hydrogel

1 areas (Fig 2M–N). We also compared the effects of biomaterial injection on immune cell
2 infiltration by immunohistochemistry of a leukocyte common antigen CD45. The density
3 of leukocytes strongly expressing CD45 (CD45^{high} cells) around the hydrogel was not
4 significantly different between the mRADA and Ncad-mRADA groups (Fig. S4).

5 We examined whether the V-SVZ-derived neuroblasts migrating along the
6 biomaterials could mature into neurons in the injured striatum using genetic labeling of
7 neural stem cells and their progeny. In Nestin-CreER;R26R-ECFP mice [43,44],
8 tamoxifen administration induces nuclear transfer of Cre recombinase in nestin promoter
9 active neural stem/progenitor cells, which results in removal of a “floxed” STOP
10 sequence at the Rosa 26 locus, leading to persistent expression of a fluorescent protein
11 ECFP. After tamoxifen injection (100 mg/kg/day, once a day for two days), these mice
12 were subjected to MCAO and biomaterial injection, and then fixed at 56 days. We found
13 some of the ECFP-labeled cells distributed along the needle tracks expressing mature
14 neuronal marker NeuN, but not Dcx (Fig. S3B-C). The number of these cells was
15 significantly higher in the Ncad-mRADA group compared with that in the mRADA group
16 (Fig. S3D), suggesting that Ncad-mRADA treatment increased generation of mature
17 neurons derived from V-SVZ neural stem/progenitor cells in the injured striatum. We
18 performed the foot-fault test, a behavior test for sensorimotor function, in these mice
19 before and after the biomaterial injection. While the intact animals show about 50% of
20 the ratio of left foot fault, the animals 12 days after right MCAO (one day before
21 biomaterial injection) increased this value to about 70% in both of the groups, reflecting
22 their sensorimotor disfunction at the contralateral limbs. The value tended to become
23 lower in Ncad-mRADA group than mRADA group, but failed to reach statistical
24 significance (Fig. S3E-G).

25 Taken together, these results indicate that Ncad-mRADA efficiently promotes
26 migration of Dcx⁺ neuroblasts toward the injured striatum in an N-cadherin-dependent
27 manner, leading to increase in mature new neurons in the post-stroke brain.

29 **Ncad-mRADA promotes neuroblast migration towards injured adult neocortex**

30 We investigated whether Ncad-mRADA promotes neuroblast migration toward the
31 neocortex after focal lesion. Two days after a cryogenic lesion was made in the parietal
32 neocortex, the self-assembling peptides were injected from the V-SVZ to the cortical
33 surface through the injured area, and brain sections were prepared five days later (Fig.
34 2O–P). Many neuroblasts were found in and around the Ncad-mRADA scaffold, but few
35 were seen in the mRADA scaffold (Fig. 2Q–R”). The number of neuroblasts in the
36 neocortex was significantly higher in the Ncad-mRADA group in areas 300 μm or more

1 from the V-SVZ (Fig. 2T). There was no significant difference in the number of
2 neuroblasts in the V-SVZ (Fig. 2S).

3 These results indicate that appropriately implanted Ncad-mRADA scaffolds can
4 promote migration of neuroblasts to injured areas in the striatum and neocortex, without
5 affecting neuroblast production in the V-SVZ.

6 7 **mRADA containing N-cadherin provides an efficient scaffold for neuroblast** 8 **migration *in vitro***

9 To precisely investigate the effect of Ncad-mRADA on neuroblast migration, we
10 performed time-lapse imaging of V-SVZ neuroblasts on culture dishes coated with
11 mRADA or Ncad-mRADA hydrogel (Fig. 3A–E). The speed of neuroblast migration
12 was significantly higher on Ncad-mRADA compared with that on mRADA (Fig. 3A–B,
13 Sup. Movie 1). The V-SVZ neuroblasts move in a saltatory manner, repeating migrating
14 and resting phases [45]. The neuroblasts on Ncad-mRADA hydrogel migrated with a
15 significantly longer stride (Fig. 3C), shorter saltatory cycle length (Fig. 3D), and shorter
16 resting phase (Fig. 3E) compared with those on mRADA. We also examined whether
17 mRADA mixed with immunoglobulin Fc domain-conjugated N-cadherin (Ncad
18 hydrogel) in which N-cadherin indirectly interacts with mRADA, likely through the Fc
19 domain, promotes neuroblast migration. There were no significant differences in
20 migration parameters between the neuroblasts on Ncad-mRADA hydrogel and those on
21 Ncad hydrogel (Fig.3B–E). Similar results were obtained in cultures using Dcx-EGFP
22 mouse V-SVZ in which neuroblasts were identified by their GFP expression (Fig. S5).
23 Therefore, in culture conditions, the promotion of neuroblast migration by N-cadherin
24 did not depend on its stable association with the mRADA hydrogel.

25 26 **Ncad-mRADA promotes neuroblast migration towards the injured neocortex in** 27 **neonatal mice**

28 We have previously reported that N-cadherin plays a key role in neuroblast
29 migration along radial glial fibers in injured neonatal neocortex [16]. Therefore, we tested
30 the effect of the Ncad-mRADA scaffold on neuroblast migration in injured neonatal
31 cortex. Postnatal day 2 (P2) animals were subjected to cryogenic injury of the parietal
32 cortex. The self-assembling peptides that form mRADA, Ncad-mRADA, or Ncad
33 hydrogels were then injected into the injured area at P5, and brain sections processed at
34 P9 (7 days post-injury). Dcx⁺ neuroblasts were abundant in the Ncad-mRADA hydrogels,
35 but sparse in the mRADA and Ncad hydrogels (Fig. 3F). The density of Dcx⁺ cells in the
36 injected areas was significantly higher in the Ncad-mRADA group compared with that in
37 mRADA or Ncad groups (Fig. 3G), indicating that Ncad-mRADA hydrogel efficiently

1 promoted neuroblast migration toward the injured neocortex *in vivo*. These data also
2 indicate that such *in vivo* effects of Ncad-mRADA depend on the stable association of N-
3 cadherin with mRADA scaffolds.

4 The neuroblasts were widely distributed above the V-SVZ, i.e., from the corpus
5 callosum to the injured cortical surface. We compared the density of neuroblasts in areas
6 at different distances from the V-SVZ between the mRADA and Ncad-mRADA groups.
7 In this analysis, the neocortex was divided into three areas: upper (superficial), middle
8 and lower (deeper) (Fig. 3H–H'). The density of neuroblasts was significantly higher in
9 the Ncad-mRADA group in the upper and middle layers, but not in the lower layer, CC,
10 or V-SVZ, compared with those in the mRADA group (Fig. 3I). Taken together, these
11 data indicate that Ncad-mRADA significantly promotes neuroblast migration toward the
12 neocortex, resulting in their widespread distribution throughout the cortical layers.

13 14 **Neuroblasts directly interact with the Ncad-mRADA scaffold to migrate into the** 15 **injured neocortex**

16 Using transmission electron microscopy, we closely observed the spatial interaction
17 between neuroblasts and transplanted Ncad-mRADA hydrogel in the neocortex 7 days
18 after cryogenic injury (Fig. 4A–H). As shown in Fig. 1D', Ncad-mRADA hydrogels were
19 well intermingled with brain tissues. To facilitate observation of Ncad-mRADA hydrogel
20 distribution in the injured brain, which contains much cell debris and many inflammatory
21 cells, we constructed selenomethionine-labeled Ncad-mRADA. Under electron
22 microscopy, the Ncad-mRADA hydrogel could be recognized as organelle-free areas
23 filled with a meshwork of small fibrous structures in necrotic tissues where activated
24 microglia containing many vacuoles and lysosomes were accumulated. As we previously
25 reported, neuroblasts were identified by their smooth and elongated cell bodies, a small
26 elongated nucleus with lax chromatin, and scant cytoplasm containing many free
27 ribosomes and microtubules [46]. Interestingly, neuroblasts occasionally formed chain-
28 like clusters (Fig. 4A–C), with small adherens junctions and free spaces between cells
29 (Fig. 4D), which are common features of chain migrating neuroblasts [46]. The cell
30 bodies of these neuroblasts directly contacted the small fibrous structures in the Ncad-
31 mRADA hydrogel (Fig. 4E). In addition, some neuroblasts migrated individually along
32 the Ncad-mRADA fibers showing radial glia-like elongated morphology (Fig. 4F–H).
33 Taken together, these observations strongly indicate that Ncad-mRADA provided an
34 efficient scaffold to help neuroblasts migrate in a chain and individually inside necrotic
35 brain tissue.

36

Ncad-mRADA promotes neuronal regeneration and sensorimotor improvement after neocortical injury

Having shown that Ncad-mRADA implantation increased the number of neuroblasts in injured neocortex (Fig. 3F–I), we then tested whether they mature into neurons and contribute to neurological recovery. To label V-SVZ-derived cells, we injected plasmids encoding Emerald Green Fluorescent Protein (EmGFP) into the lateral ventricle of P0 mice, and introduced them into the periventricular cells using an electroporator. After cryogenic injury at P2 and scaffold injection at P5, expression of neuronal markers in the EmGFP-labeled cells were examined (Fig. 5A). At P9, some of the EmGFP cells in the corpus callosum and neocortex expressed Dcx, but not NeuN, regardless of the type of injected biomaterials (Fig. S6A–B). At P30, the damaged tissues were shrunk but were still distinguishable in coronal brain sections. The mRADA and Ncad-mRADA scaffolds were mostly disappeared by 4 weeks after injection (Fig 5B). We examined the distribution of V-SVZ-derived (EmGFP-labeled) cells that express the mature neuron marker NeuN in the injured area. Most of the EmGFP+NeuN+ cells were observed in the vicinity of the injury scars (Fig. 5B–C). These cells also expressed MAP2 (Fig. 5D), another marker for mature neurons, and GAD67, a marker for GABAergic neurons (Fig. 5E). These cells developed long and branched processes with many spines (Fig. 5C), a typical morphology of mature neurons. We found localization of inhibitory post-synaptic membrane protein Gephyrin in these spines (Fig. 5F), suggesting that these cells were mature functional neurons. The percentage of cortical EmGFP+NeuN+ cells distributed in the upper layer was significantly higher in the Ncad-mRADA group, compared with that in the mRADA group (Fig. 5G). Overall, the Ncad-mRADA scaffold helped neuroblast migration toward the lesion, which resulted in an increased number of new mature neurons in the upper layer of the neocortex, the most seriously damaged layer in this injury model.

The mice after neonatal cortical injury were subjected to three kinds of quantitative neurological assessments, the foot-fault test, automatic gait analysis and elevated body swing test at P29–35 (Fig. 5A). In the foot-fault test, we calculated the percentage of missteps (% error) in all steps of the hind limbs during the 5-min trial (Fig. 5H). The false rate was significantly increased in the group subjected to the cryogenic lesion without subsequent intervention. Mice with the Ncad-mRADA hydrogel, but not the mRADA hydrogel or non-histocompatible RADA hydrogel (Fig. 1A–A’), exhibited a significant decrease in the false rate, which was comparable to that in intact animals (Fig. 5H, S6E). In the automatic gait analysis, among various parameters automatically measured during free walking, we previously found that the maximum contact areas of the left fore and hind paws were significantly reduced in mice after right cortical injury [16]. Such injury-

1 induced alterations were cancelled in mice treated with Ncad-mRADA, but not mRADA
2 (Fig. 5I-J). Elevated body swing test could efficiently detect asymmetric body movement
3 in rodents. While intact animals swing their body to the left and right with almost the
4 same rate, the neocortical injury significantly decreased the percentage of body swing to
5 the right. Ncad-mRADA, but not mRADA hydrogel treatment significantly increased the
6 ratio to the level comparable to that in the intact animals (Fig. S6C-D).

7 Finally, we examined whether the V-SVZ-derived new neurons were involved
8 in sensorimotor improvement in mice injected with Ncad-mRADA peptide. We used
9 NSE-DTA mice in which neuronal cells are selectively eliminated depending on Cre
10 recombinase expression [29,36]. The NSE-DTA mice and wild-type mice were subjected
11 to electroporation of EmGFP plasmid to label V-SVZ cells at P0, followed by injection
12 of adenovirus encoding cre into the lateral ventricle at P1, cortical injury at P2, and Ncad-
13 mRADA injection at P5 (Fig. 5K). At P30, the number of EmGFP-labeled (V-SVZ-
14 derived) cells expressing NeuN was significantly smaller in NSE-DTA mice compared
15 with that in wild-type mice (Fig. 5L). The percentage of left paw missteps in the foot-
16 fault test was also significantly higher in the NSE-DTA group than wild-type group (Fig.
17 5M), suggesting that the V-SVZ-derived new neurons contributed to the Ncad-RADA
18 peptide treatment induced improvement in sensorimotor function. Taken together, these
19 results indicate that Ncad-mRADA efficiently promotes neuronal regeneration and
20 recovery of sensorimotor function after neonatal brain injury.

21 22 **Discussion**

23 In this study, we developed Ncad-mRADA, an injectable biomaterial based on the
24 structural and molecular features of radial glia, which forms an efficient migration
25 scaffold for V-SVZ-derived neuroblasts in the postnatal brain. This scaffold successfully
26 facilitated the migration of neuroblasts into deep and superficial lesions and promoted
27 improvement in sensorimotor functions.

28 The mRADA hydrogel did not induce an excessive inflammatory response in the
29 brain parenchyma (Fig. 1). Compared with the hydrogel formed by the original self-
30 assembling peptide, RADA, the mRADA hydrogel showed greater ability to integrate
31 into the surrounding tissue (Fig. 1) and to induce ectopic neuroblast migration to the
32 striatum, which is distant from the V-SVZ (Fig. S2). Transmission electron microscopy
33 revealed that mRADA hydrogel formed fine fibrous aggregates dispersed in parenchymal
34 tissue (Fig. 1). The morphology of the mRADA hydrogel in tissue was in concordance
35 with atomic molecular dynamics simulations that predicted fibrillar assembly with
36 branched structures [27]. In addition, the highly fluid mRADA peptides could be

1 distributed more widely in the tissue surrounding the injection needle before aggregates
2 formed compared with RADA peptides (Fig. 1A–D).

3 Notably, more than half of the ectopic neuroblasts were observed in regions ≥ 100
4 μm from the injection trajectory, where the Alexa647-azide signal was undetectable (Fig.
5 S2). Considering that the Ncad-mRADA hydrogel showed a distribution profile similar
6 to that of the mRADA hydrogel (data not shown), it is likely that these neuroblasts utilized
7 the fine fibers of the Ncad-mRADA hydrogel that are not detectable with Alexa647-azide
8 under light microscopy. Such a distribution profile is desirable for supplying neuroblasts
9 throughout a lesion via a single injection (Fig. 2–3). Large aggregates of mRADA/Ncad-
10 mRADA hydrogels labeled with Alexa647-azide were not detected by light microscopy
11 at 4 weeks post-injection (Fig. 5), indicating that the hydrogels were degraded after the
12 active period of tissue remodeling, a desirable feature of scaffold materials that promote
13 tissue regeneration [1,47].

14 Radial glial cells are well-studied scaffold cells for neuroblasts in the embryonic
15 brain. They extend a long process from the cell body, which is located in the ventricular
16 zone, to the pial surface to serve as a scaffold for neuroblasts migrating into the neocortex
17 during morphogenesis and after neonatal cortical injury. In both cases, the interaction
18 between radial glia and migrating neuroblasts is mediated by N-cadherin [16,48]. Radial
19 glial cells disappear within several weeks after birth [49]; therefore, neuroblasts use other
20 scaffolds, such as blood vessels, and depend on $\beta 1$ integrin-laminin signaling to reach
21 injured areas in the adult brain [13]. Neuroblasts form chain-like elongated clusters to
22 provide a scaffold for each other in the adult rostral migratory stream. N-cadherin is
23 expressed in these adult-born neuroblasts [50] and in neuroblasts in the embryonic and
24 neonatal brain, and is involved in neuroblast migration in the adult brain [51]. However,
25 its application to the development of artificial scaffolds that mimic radial glial fibers has
26 not been demonstrated. Here, we demonstrated that a biomaterial that forms radial glia-
27 like fibers connecting the V-SVZ to a site of injury serves as an efficient scaffold that
28 promotes neuroblast migration in an N-cadherin-dependent manner. The direct contact
29 between neuroblasts and the biomaterial (Fig. 4) and the absence of astrocytes or blood
30 vessels between them indicate that the preference for N-cadherin-containing scaffolds is
31 maintained throughout life as a common feature of migrating neuroblasts.

32 Ncad-mRADA was constructed to stably and specifically associate the full-length
33 N-cadherin extracellular domain tagged with mRADA to supramolecular nanofibers
34 during mRADA self-assembly (Fig. 1G). The self-assembling mRADA forms a β -sheet
35 structure in water through non-covalent interactions, such as hydrogen bonding and
36 hydrophobic interactions. Given the capability of mRADA to form multivalent non-
37 covalent interactions, it is likely that Ncad-mRADA assembles stably with mRADA

1 peptides. However, in “Ncad hydrogel” prepared by mixing Ncad-Fc with mRADA, the
2 association of Ncad-Fc with the mRADA nanofibers was unstable because the association
3 of Ncad-Fc depends on non-specific adsorption [30]. Both of these materials contained
4 similar amounts of N-cadherin initially, but the Ncad hydrogel released the N-cadherin
5 extracellular domain more rapidly during cell-free incubation (Fig. 1). After V-SVZ
6 neuroblasts were cultured for 48 h, time-lapse imaging revealed that both Ncad-mRADA
7 and Ncad hydrogels promoted neuroblast migration compared with the mRADA hydrogel
8 (Fig. 3). However, histological analyses performed five days after injection into injured
9 neocortex showed that neuroblast migration was promoted by Ncad-mRADA but not by
10 Ncad hydrogel (Fig. 3). These results indicate that the stability of N-cadherin association
11 is more important in tissue *in vivo* than in *in vitro* culture conditions. The persistence of
12 neuroblast migration toward an injured area for at least one week [14], depending on the
13 animal model, indicates that persistent N-cadherin activity might be critical for successful
14 brain regeneration.

15 After termination of migration in the injured neocortex of neonatal mice, the V-
16 SVZ-derived neuroblasts mature into neurons possessing long, branched neurites on
17 which inhibitory synapses were formed (Fig. 5D-E). While the precise roles of these new
18 neurons are still unknown, deletion of these new neurons using a genetic method cancels
19 functional recovery in mice treated with Ncad-mRADA peptide (Fig. 5M). This indicates
20 that the new neurons are involved in neuronal rewiring after injury. Considering the
21 presence of extensive neuroblast migration into the neonatal human cortex [52], these
22 data indicate that Ncad-mRADA fibers will be useful for the treatment of human neonatal
23 brain injury. The Ncad-mRADA hydrogel also promoted neuroblast migration in the post-
24 stroke adult brain (Fig. 2), and a small portion of these neuroblasts matured into NeuN+
25 neurons in the striatum (Fig. S3), but failed to cause statistically significant improvement
26 in sensorimotor function (Fig. S3). In general, plasticity of neuronal circuits decreases
27 with age [53]. Similarly, neurogenic activity in the V-SVZ is very high during the neonatal
28 period but declines sharply within a month [54,55]. The decline in neurogenesis during
29 postnatal development is more striking in primates, including humans [56–58]. Therefore,
30 successful rewiring in adulthood requires more effective strategies that can maximize the
31 utility of the limited number of newly born neurons. Self-assembling peptides containing
32 a short functional peptide (for example, the RGD motif) that binds to integrins in the
33 extracellular matrix promote axonal extension and neuroblast migration [26,59,60].
34 However full length protein domains also differentially mediate cell morphology, cell
35 migration and cell proliferation compared with short peptide motifs alone [61]. Many
36 proteins other than those that mediate cell adhesion cannot exert their functions with such
37 a short sequence. Here, we have developed a technology for incorporating more than 100

1 kDa of full-length N-cadherin extracellular domain into the histocompatible self-
2 assembling peptide, mRADA. This technique can be applied to incorporate other
3 molecules with relatively large molecular sizes into injectable scaffolds. The scaffold-
4 guided migration of neuroblasts in the injured brain depends on not only cell adhesion
5 molecules but also diffusible factors such as BDNF released from the scaffolds [62].
6 Using a technique to release a diffusible factor from injectable nanofibers [30], in
7 combination with the stable incorporation of cell adhesion molecules, it should be
8 possible to design more effective biomaterials as migration scaffolds to continuously
9 support neurogenesis until maturation in the injured brain.

11 **Acknowledgements**

12 The authors thank Mr. Jiro Nagase for technical support. The authors acknowledge the
13 assistance of the Research Equipment Sharing Center at Nagoya City University. The
14 authors also thank Sawamoto laboratory members for discussions and Jeremy Allen, PhD,
15 from Edanz (<https://jp.edanz.com/ac>) for editing a draft of this manuscript.

17 **Author contributions**

18 Y Ohno: Formal analysis, Investigation, Validation, Visualization, Writing - original draft
19 and editing. C Nakajima: Formal analysis, Investigation, Validation, Visualization,
20 Writing - original draft and editing. I Ajioka: Resources, Formal analysis, Investigation,
21 Validation, Visualization, Writing - original draft and editing. T Muraoka: Resources,
22 Investigation, Validation, Visualization, Writing - original draft and editing. A Yaguchi:
23 Resources. T Fujioka: Investigation. S Akimoto: Resources. M Matsuo: Investigation. A
24 Lotfy: Investigation. S Nakamura: Formal analysis, Investigation. V Herranz-Pérez:
25 Validation, Supervision. J M García-Verdugo: Validation, Supervision. N Matsukawa:
26 Supervision. N Kaneko: Conceptualization, Formal analysis, Funding acquisition,
27 Investigation, Supervision, Validation, Visualization, Writing - original draft, Writing -
28 review and editing. K Sawamoto: Conceptualization, Funding acquisition, Project
29 administration, Supervision, Writing - review and editing.

31 **Funding**

32 This work was supported by the Japan Agency for Medical Research and Development
33 AMED [JP21bm0704033h0003 and JP21gm1210007 to K.S. and JP21jm0210060h0004
34 to N.K., I.A. and K.S.]; the Japan Society for the Promotion of Science (JSPS) KAKENHI
35 [17H01392, 19H04757, 19H04785, 18KK0213, and 20H05700 to K.S. and 20H03565,
36 21H05106 to N.K.]; the Spanish Ministry of Science, Innovation and Universities
37 [PCI2018–093062 to V.H-P. and J.M.G-V.]; the Spain Cell Therapy Network [TerCel-

1 RD16/0011/0026 to J.M.G-V.]; the JST FOREST Program (JPMJFR2146) to N.K.
2 Bilateral Open Partnership Joint Research Projects [JPJSBP120229939 to N.K.]; Grant-
3 in-Aid for Research at Nagoya City University [to N.K. and K.S.]; the Mitsubishi
4 Foundation [to K.S.]; the Takeda Science Foundation [to N.K. and K.S.] and the Canon
5 Foundation [to K.S. and I.A.].

7 **Declaration of competing interest**

8 The authors declare no competing interests.

10 **Data availability**

11 The data presented in this study are available on request from the corresponding authors.

14 **References**

- 15 [1] M.I. Echeverria Molina, K.G. Malollari, K. Komvopoulos, Design Challenges in
16 Polymeric Scaffolds for Tissue Engineering, *Front. Bioeng. Biotechnol.* 9 (2021)
17 1–29. <https://doi.org/10.3389/fbioe.2021.617141>.
- 18 [2] T. Santos, C. Boto, C.M. Saraiva, L. Bernardino, L. Ferreira, Nanomedicine
19 Approaches to Modulate Neural Stem Cells in Brain Repair, *Trends Biotechnol.*
20 34 (2016) 437–439. <https://doi.org/10.1016/j.tibtech.2016.02.003>.
- 21 [3] A. Cembran, K.F. Bruggeman, R.J. Williams, C.L. Parish, D.R. Nisbet,
22 Biomimetic Materials and Their Utility in Modeling the 3-Dimensional Neural
23 Environment, *IScience.* 23 (2020) 100788.
24 <https://doi.org/10.1016/j.isci.2019.100788>.
- 25 [4] D. Carradori, J. Eyer, P. Saulnier, V. Pr eat, A. des Rieux, The therapeutic
26 contribution of nanomedicine to treat neurodegenerative diseases via neural stem
27 cell differentiation, *Biomaterials.* 123 (2017) 77–91.
28 <https://doi.org/10.1016/j.biomaterials.2017.01.032>.
- 29 [5] K. Obernier, A. Alvarez-Buylla, Neural stem cells: origin, heterogeneity and
30 regulation in the adult mammalian brain, *Development.* 146 (2019) dev156059.
31 <https://doi.org/10.1242/dev.156059>.
- 32 [6] C. Nakajima, M. Sawada, K. Sawamoto, Postnatal neuronal migration in health
33 and disease, *Curr. Opin. Neurobiol.* 66 (2021) 1–9.
34 <https://doi.org/10.1016/j.conb.2020.06.001>.
- 35 [7] H. Wichterle, J.M. Garc a-Verdugo, A. Alvarez-Buylla, Direct Evidence for
36 Homotypic, Glia-Independent Neuronal Migration, *Neuron.* 18 (1997) 779–791.
37 [https://doi.org/10.1016/S0896-6273\(00\)80317-7](https://doi.org/10.1016/S0896-6273(00)80317-7).

- 1 [8] C. Lois, J.M. García-Verdugo, A. Alvarez-Buylla, Chain migration of neuronal
2 precursors, *Science* (80-.). 271 (1996) 978–981.
3 <https://doi.org/10.1126/science.271.5251.978>.
- 4 [9] P. Thored, A. Arvidsson, E. Cacci, H. Ahlenius, T. Kallur, V. Darsalia, C.T.
5 Ekdahl, Z. Kokaia, O. Lindvall, Persistent Production of Neurons from Adult
6 Brain Stem Cells During Recovery after Stroke, *Stem Cells*. 24 (2006) 739–747.
7 <https://doi.org/10.1634/stemcells.2005-0281>.
- 8 [10] D. Alagappan, D.A. Lazzarino, R.J. Felling, M. Balan, S. V Kottenko, S.W.
9 Levison, Brain Injury Expands the Numbers of Neural Stem Cells and
10 Progenitors in the SVZ by Enhancing Their Responsiveness to EGF, *ASN Neuro*.
11 1 (2009) AN20090002. <https://doi.org/10.1042/AN20090002>.
- 12 [11] E. Llorens-Bobadilla, S. Zhao, A. Baser, G. Saiz-Castro, K. Zwadlo, A. Martin-
13 Villalba, Single-Cell Transcriptomics Reveals a Population of Dormant Neural
14 Stem Cells that Become Activated upon Brain Injury, *Cell Stem Cell*. 17 (2015)
15 329–340. <https://doi.org/10.1016/j.stem.2015.07.002>.
- 16 [12] T. Yamashita, M. Ninomiya, P.H. Acosta, J.M. García-Verdugo, T. Sunabori, M.
17 Sakaguchi, K. Adachi, T. Kojima, Y. Hirota, T. Kawase, N. Araki, K. Abe, H.
18 Okano, K. Sawamoto, Subventricular zone-derived neuroblasts migrate and
19 differentiate into mature neurons in the post-stroke adult striatum, *J. Neurosci*. 26
20 (2006) 6627–6636. <https://doi.org/10.1523/JNEUROSCI.0149-06.2006>.
- 21 [13] T. Fujioka, N. Kaneko, I. Ajioka, K. Nakaguchi, T. Omata, H. Ohba, R. Fässler,
22 J.M. García-Verdugo, K. Sekiguchi, N. Matsukawa, K. Sawamoto, β 1 integrin
23 signaling promotes neuronal migration along vascular scaffolds in the post-stroke
24 brain, *EBioMedicine*. 16 (2017) 195–203.
25 <https://doi.org/10.1016/j.ebiom.2017.01.005>.
- 26 [14] P. Thored, J. Wood, A. Arvidsson, J. Cammenga, Z. Kokaia, O. Lindvall, Long-
27 term neuroblast migration along blood vessels in an area with transient
28 angiogenesis and increased vascularization after stroke, *Stroke*. 38 (2007) 3032–
29 3039. <https://doi.org/10.1161/STROKEAHA.107.488445>.
- 30 [15] M. Snopyan, M. Lemasson, M.S. Brill, M. Blais, M. Massouh, J. Ninkovic, C.
31 Gravel, F. Berthod, M. Götz, P.A. Barker, A. Parent, A. Saghatelian, Vasculature
32 guides migrating neuronal precursors in the adult mammalian forebrain via brain-
33 derived neurotrophic factor signaling, *J. Neurosci*. 29 (2009) 4172–4188.
34 <https://doi.org/10.1523/JNEUROSCI.4956-08.2009>.
- 35 [16] H. Jinnou, M. Sawada, K. Kawase, N. Kaneko, V. Herranz-Pérez, T. Miyamoto,
36 T. Kawaue, T. Miyata, Y. Tabata, T. Akaike, J.M. García-Verdugo, I. Ajioka, S.
37 Saitoh, K. Sawamoto, Radial Glial Fibers Promote Neuronal Migration and

- 1 Functional Recovery after Neonatal Brain Injury, *Cell Stem Cell*. 22 (2018) 128-
2 137.e9. <https://doi.org/10.1016/j.stem.2017.11.005>.
- 3 [17] N. Kaneko, V. Herranz-Pérez, T. Otsuka, H. Sano, N. Ohno, T. Omata, H.B.
4 Nguyen, T.Q. Thai, A. Nambu, Y. Kawaguchi, J.M. García-Verdugo, K.
5 Sawamoto, New neurons use Slit-Robo signaling to migrate through the glial
6 meshwork and approach a lesion for functional regeneration, *Sci. Adv.* 4 (2018).
7 <https://doi.org/10.1126/sciadv.aav0618>.
- 8 [18] N.S. Roy, C. Cleren, S.K. Singh, L. Yang, M.F. Beal, S.A. Goldman, Functional
9 engraftment of human ES cell-derived dopaminergic neurons enriched by
10 coculture with telomerase-immortalized midbrain astrocytes, *Nat. Med.* 12
11 (2006) 1259–1268. <https://doi.org/10.1038/nm1495>.
- 12 [19] T. Yamashita, H. Kawai, F. Tian, Y. Ohta, K. Abe, Tumorigenic Development of
13 Induced Pluripotent Stem Cells in Ischemic Mouse Brain, *Cell Transplant.* 20
14 (2011) 883–892. <https://doi.org/10.3727/096368910X539092>.
- 15 [20] K. Ohnishi, K. Semi, T. Yamamoto, M. Shimizu, A. Tanaka, K. Mitsunaga, K.
16 Okita, K. Osafune, Y. Arioka, T. Maeda, H. Soejima, H. Moriwaki, S.
17 Yamanaka, K. Woltjen, Y. Yamada, Premature Termination of Reprogramming
18 In Vivo Leads to Cancer Development through Altered Epigenetic Regulation,
19 *Cell*. 156 (2014) 663–677. <https://doi.org/10.1016/j.cell.2014.01.005>.
- 20 [21] I. Ajioka, H. Jinnou, K. Okada, M. Sawada, S. Saitoh, K. Sawamoto,
21 Enhancement of neuroblast migration into the injured cerebral cortex using
22 laminin-containing porous sponge, *Tissue Eng. - Part A*. 21 (2015) 193–201.
23 <https://doi.org/10.1089/ten.tea.2014.0080>.
- 24 [22] M.R. Caplan, P.N. Moore, S. Zhang, R.D. Kamm, D.A. Lauffenburger, Self-
25 Assembly of a β -Sheet Protein Governed by Relief of Electrostatic Repulsion
26 Relative to van der Waals Attraction, *Biomacromolecules*. 1 (2000) 627–631.
27 <https://doi.org/10.1021/bm005586w>.
- 28 [23] G.A. Silva, C. Czeisler, K.L. Niece, E. Beniash, D.A. Harrington, J.A. Kessler,
29 S.I. Stupp, Selective Differentiation of Neural Progenitor Cells by High-Epitope
30 Density Nanofibers, *Science* (80-.). 303 (2004) 1352–1355.
31 <https://doi.org/10.1126/science.1093783>.
- 32 [24] H. Yokoi, T. Kinoshita, S. Zhang, Dynamic reassembly of peptide RADA16
33 nanofiber scaffold, *Proc. Natl. Acad. Sci.* 102 (2005) 8414–8419.
34 <https://doi.org/10.1073/pnas.0407843102>.
- 35 [25] S. Motamed, M.P. Del Borgo, K. Zhou, K. Kulkarni, P.J. Crack, T.D. Merson,
36 M.I. Aguilar, D.I. Finkelstein, J.S. Forsythe, Migration and Differentiation of
37 Neural Stem Cells Diverted From the Subventricular Zone by an Injectable Self-

- 1 Assembling β -Peptide Hydrogel, *Front. Bioeng. Biotechnol.* 7 (2019) 1–12.
2 <https://doi.org/10.3389/fbioe.2019.00315>.
- 3 [26] R. Motalleb, E.J. Berns, P. Patel, J. Gold, S.I. Stupp, H.G. Kuhn, In vivo
4 migration of endogenous brain progenitor cells guided by an injectable peptide
5 amphiphile biomaterial, *J. Tissue Eng. Regen. Med.* 12 (2018) e2123–e2133.
6 <https://doi.org/10.1002/term.2644>.
- 7 [27] A. Ishida, G. Watanabe, M. Oshikawa, I. Ajioka, T. Muraoka, Glycine
8 Substitution Effects on the Supramolecular Morphology and Rigidity of Cell-
9 Adhesive Amphiphilic Peptides, *Chem. - A Eur. J.* (2019).
10 <https://doi.org/10.1002/chem.201902083>.
- 11 [28] S. Gong, C. Zheng, M.L. Doughty, K. Losos, N. Didkovsky, U.B. Schambra, N.J.
12 Nowak, A. Joyner, G. Leblanc, M.E. Hatten, N. Heintz, A gene expression atlas
13 of the central nervous system based on bacterial artificial chromosomes, *Nature*.
14 425 (2003) 917–925. <https://doi.org/10.1038/nature02033>.
- 15 [29] K. Kobayakawa, R. Kobayakawa, H. Matsumoto, Y. Oka, T. Imai, M. Ikawa, M.
16 Okabe, T. Ikeda, S. Itohara, T. Kikusui, K. Mori, H. Sakano, Innate versus
17 learned odour processing in the mouse olfactory bulb, *Nature*. 450 (2007) 503–
18 508. <https://doi.org/10.1038/nature06281>.
- 19 [30] A. Yaguchi, M. Oshikawa, G. Watanabe, H. Hiramatsu, N. Uchida, C. Hara, N.
20 Kaneko, K. Sawamoto, T. Muraoka, I. Ajioka, Efficient protein incorporation and
21 release by a jigsaw-shaped self-assembling peptide hydrogel for injured brain
22 regeneration, *Nat. Commun.* 2021 121. 12 (2021) 1–12.
23 <https://doi.org/10.1038/s41467-021-26896-3>.
- 24 [31] M. Oshikawa, K. Okada, H. Tabata, K. Nagata, I. Ajioka, Dnmt1-dependent
25 Chk1 pathway suppression is protective against neuron division, *Development*.
26 144 (2017) 3303–3314. <https://doi.org/10.1242/dev.154013>.
- 27 [32] X.-S. Yue, Y. Murakami, T. Tamai, M. Nagaoka, C.-S. Cho, Y. Ito, T. Akaike, A
28 fusion protein N-cadherin-Fc as an artificial extracellular matrix surface for
29 maintenance of stem cell features, *Biomaterials*. 31 (2010) 5287–5296.
30 <https://doi.org/10.1016/j.biomaterials.2010.03.035>.
- 31 [33] M. Sawada, M. Matsumoto, K. Narita, N. Kumamoto, S. Ugawa, S. Takeda, K.
32 Sawamoto, In vitro Time-lapse Imaging of Primary Cilium in Migrating
33 Neuroblasts, *Bio-Protocol*. 10 (2020) 1–17.
34 <https://doi.org/10.21769/bioprotoc.3823>.
- 35 [34] H. Hara, P.L. Huang, N. Panahian, M.C. Fishman, M.A. Moskowitz, Reduced
36 Brain Edema and Infarction Volume in Mice Lacking the Neuronal Isoform of


- 1 Nitric Oxide Synthase after Transient MCA Occlusion, *J. Cereb. Blood Flow*
2 *Metab.* 16 (1996) 605–611. <https://doi.org/10.1097/00004647-199607000-00010>.
- 3 [35] H. Ota, T. Hikita, M. Sawada, T. Nishioka, M. Matsumoto, M. Komura, A.
4 Ohno, Y. Kamiya, T. Miyamoto, N. Asai, A. Enomoto, M. Takahashi, K.
5 Kaibuchi, K. Sobue, K. Sawamoto, Speed control for neuronal migration in the
6 postnatal brain by Gmip-mediated local inactivation of RhoA, *Nat. Commun.* 5
7 (2014) 4532. <https://doi.org/10.1038/ncomms5532>.
- 8 [36] I. Imayoshi, M. Sakamoto, T. Ohtsuka, K. Takao, T. Miyakawa, M. Yamaguchi,
9 K. Mori, T. Ikeda, S. Itohara, R. Kageyama, Roles of continuous neurogenesis in
10 the structural and functional integrity of the adult forebrain., *Nat. Neurosci.* 11
11 (2008) 1153–61. <https://doi.org/10.1038/nn.2185>.
- 12 [37] T.D. Hernandez, T. Schallert, Seizures and recovery from experimental brain
13 damage, *Exp. Neurol.* 102 (1988) 318–324. [https://doi.org/10.1016/0014-](https://doi.org/10.1016/0014-4886(88)90226-9)
14 [4886\(88\)90226-9](https://doi.org/10.1016/0014-4886(88)90226-9).
- 15 [38] Y. Benjamini, D. Drai, G. Elmer, N. Kafkafi, I. Golani, Controlling the false
16 discovery rate in behavior genetics research, *Behav. Brain Res.* 125 (2001) 279–
17 284. [https://doi.org/10.1016/S0166-4328\(01\)00297-2](https://doi.org/10.1016/S0166-4328(01)00297-2).
- 18 [39] Y. Benjamini, A.M. Krieger, D. Yekutieli, Adaptive linear step-up procedures
19 that control the false discovery rate, *Biometrika.* 93 (2006) 491–507.
20 <https://doi.org/10.1093/biomet/93.3.491>.
- 21 [40] C. Lois, A. Alvarez-Buylla, Long-distance neuronal migration in the adult
22 mammalian brain, *Science* (80-.). 264 (1994) 1145–1148.
23 <https://doi.org/10.1126/science.8178174>.
- 24 [41] J.M. Parent, Z.S. Vexler, C. Gong, N. Derugin, D.M. Ferriero, Rat forebrain
25 neurogenesis and striatal neuron replacement after focal stroke, *Ann. Neurol.* 52
26 (2002) 802–813. <https://doi.org/10.1002/ana.10393>.
- 27 [42] A. Arvidsson, T. Collin, D. Kirik, Z. Kokaia, O. Lindvall, Neuronal replacement
28 from endogenous precursors in the adult brain after stroke, *Nat. Med.* 8 (2002)
29 963–970. <https://doi.org/10.1038/nm747>.
- 30 [43] I. Imayoshi, T. Ohtsuka, D. Metzger, P. Chambon, R. Kageyama, Temporal
31 regulation of Cre recombinase activity in neural stem cells, *Genesis.* 44 (2006)
32 233–238. <https://doi.org/10.1002/dvg.20212>.
- 33 [44] S. Srinivas, T. Watanabe, C.S. Lin, C.M. Williams, Y. Tanabe, T.M. Jessell, F.
34 Costantini, Cre reporter strains produced by targeted insertion of EYFP and
35 ECFP into the ROSA26 locus., *BMC Dev. Biol.* 1 (2001) 4.
36 <https://doi.org/10.1186/1471-213x-1-4>.

- 1 [45] N. Kaneko, M. Sawada, K. Sawamoto, Mechanisms of neuronal migration in the
2 adult brain, *J. Neurochem.* 141 (2017) 835–847.
3 <https://doi.org/10.1111/jnc.14002>.
- 4 [46] F. Doetsch, J.M. García-Verdugo, A. Alvarez-Buylla, Cellular Composition and
5 Three-Dimensional Organization of the Subventricular Germinal Zone in the
6 Adult Mammalian Brain, *J. Neurosci.* 17 (1997) 5046–5061.
7 <https://doi.org/10.1523/JNEUROSCI.17-13-05046.1997>.
- 8 [47] R. Boni, A. Ali, A. Shavandi, A.N. Clarkson, Current and novel polymeric
9 biomaterials for neural tissue engineering, *J. Biomed. Sci.* 25 (2018) 90.
10 <https://doi.org/10.1186/s12929-018-0491-8>.
- 11 [48] M. Shikanai, K. Nakajima, T. Kawauchi, N-Cadherin regulates radial glial fiber-
12 dependent migration of cortical locomoting neurons, *Commun. Integr. Biol.* 4
13 (2011) 326–330. <https://doi.org/10.4161/cib.4.3.14886>.
- 14 [49] A. Kriegstein, A. Alvarez-Buylla, The glial nature of embryonic and adult neural
15 stem cells., *Annu. Rev. Neurosci.* 32 (2009) 149–184.
16 <https://doi.org/10.1146/annurev.neuro.051508.135600>.
- 17 [50] Y. Yagita, T. Sakurai, H. Tanaka, K. Kitagawa, D.R. Colman, W. Shan, N-
18 cadherin mediates interaction between precursor cells in the subventricular zone
19 and regulates further differentiation, *J. Neurosci. Res.* 87 (2009) 3331–3342.
20 <https://doi.org/10.1002/jnr.22044>.
- 21 [51] E. Porlan, B. Martí-Prado, J.M. Morante-Redolat, A. Consiglio, A.C. Delgado, R.
22 Kypta, C. López-Otín, M. Kirstein, I. Fariñas, MT5-MMP regulates adult neural
23 stem cell functional quiescence through the cleavage of N-cadherin, *Nat. Cell*
24 *Biol.* 16 (2014) 629–638. <https://doi.org/10.1038/ncb2993>.
- 25 [52] M.F. Paredes, D. James, S. Gil-Perotin, H. Kim, J.A. Cotter, C. Ng, K. Sandoval,
26 D.H. Rowitch, D. Xu, P.S. McQuillen, J.M. Garcia-Verdugo, E.J. Huang, A.
27 Alvarez-Buylla, Extensive migration of young neurons into the infant human
28 frontal lobe, *Science* (80-.). 354 (2016). <https://doi.org/10.1126/science.aaf7073>.
- 29 [53] A. Denoth-Lippuner, S. Jessberger, Formation and integration of new neurons in
30 the adult hippocampus, *Nat. Rev. Neurosci.* 22 (2021) 223–236.
31 <https://doi.org/10.1038/s41583-021-00433-z>.
- 32 [54] V. Capilla-Gonzalez, V. Herranz-Pérez, J.M. García-Verdugo, The aged brain:
33 genesis and fate of residual progenitor cells in the subventricular zone, *Front.*
34 *Cell. Neurosci.* 9 (2015). <https://doi.org/10.3389/fncel.2015.00365>.
- 35 [55] M.P. Jurkowski, L. Bettio, E. K. Woo, A. Patten, S.-Y. Yau, J. Gil-Mohapel,
36 Beyond the Hippocampus and the SVZ: Adult Neurogenesis Throughout the

- 1 Brain, *Front. Cell. Neurosci.* 14 (2020).
2 <https://doi.org/10.3389/fncel.2020.576444>.
- 3 [56] A. Quiñones-Hinojosa, N. Sanai, M. Soriano-Navarro, O. Gonzalez-Perez, Z.
4 Mirzadeh, S. Gil-Perotin, R. Romero-Rodriguez, M.S. Berger, J.M. Garcia-
5 Verdugo, A. Alvarez-Buylla, Cellular composition and cytoarchitecture of the
6 adult human subventricular zone: A niche of neural stem cells, *J. Comp. Neurol.*
7 494 (2006) 415–434. <https://doi.org/10.1002/cne.20798>.
- 8 [57] M. Akter, N. Kaneko, V. Herranz-Pérez, S. Nakamura, H. Oishi, J.M. García-
9 Verdugo, K. Sawamoto, Dynamic Changes in the Neurogenic Potential in the
10 Ventricular–Subventricular Zone of Common Marmoset during Postnatal Brain
11 Development, *Cereb. Cortex.* 30 (2020) 4092–4109.
12 <https://doi.org/10.1093/cercor/bhaa031>.
- 13 [58] N. Sanai, T. Nguyen, R.A. Ihrie, Z. Mirzadeh, H.-H. Tsai, M. Wong, N. Gupta,
14 M.S. Berger, E. Huang, J.-M. Garcia-Verdugo, D.H. Rowitch, A. Alvarez-
15 Buylla, Corridors of migrating neurons in the human brain and their decline
16 during infancy, *Nature.* 478 (2011) 382–386.
17 <https://doi.org/10.1038/nature10487>.
- 18 [59] E.J. Berns, S. Sur, L. Pan, J.E. Goldberger, S. Suresh, S. Zhang, J.A. Kessler, S.I.
19 Stupp, Aligned neurite outgrowth and directed cell migration in self-assembled
20 monodomain gels, *Biomaterials.* 35 (2014) 185–195.
21 <https://doi.org/10.1016/j.biomaterials.2013.09.077>.
- 22 [60] V.M. Tysseling-Mattiace, V. Sahni, K.L. Niece, D. Birch, C. Czeisler, M.G.
23 Fehlings, S.I. Stupp, J.A. Kessler, Self-assembling nanofibers inhibit glial scar
24 formation and promote axon elongation after spinal cord injury, *J. Neurosci.* 28
25 (2008) 3814–3823. <https://doi.org/10.1523/JNEUROSCI.0143-08.2008>.
- 26 [61] E. Fong, D.A. Tirrell, Collective Cell Migration on Artificial Extracellular Matrix
27 Proteins Containing Full-Length Fibronectin Domains, *Adv. Mater.* 22 (2010)
28 5271–5275. <https://doi.org/10.1002/adma.201002448>.
- 29 [62] S. Grade, Y.C. Weng, M. Snopyan, J. Kriz, J.O. Malva, A. Saghatelian, Brain-
30 Derived Neurotrophic Factor Promotes Vasculature-Associated Migration of
31 Neuronal Precursors toward the Ischemic Striatum, *PLoS One.* 8 (2013).
32 <https://doi.org/10.1371/journal.pone.0055039>.
- 33 [63] S. Srinivas, T. Watanabe, C.S. Lin, C.M. Williams, Y. Tanabe, T.M. Jessell, F.
34 Costantini, Cre reporter strains produced by targeted insertion of EYFP and
35 ECFP into the ROSA26 locus., *BMC.* 1 (2001) 4. [https://doi.org/10.1186/1471-](https://doi.org/10.1186/1471-213x-1-4)
36 213x-1-4.

- 1 [64] C. V. Borlongan, T.S. Randall, D.W. Cahill, P.R. Sanberg, Asymmetrical motor
2 behavior in rats with unilateral striatal excitotoxic lesions as revealed by the
3 elevated body swing test, *Brain Res.* 676 (1995) 231–234.
4 [https://doi.org/10.1016/0006-8993\(95\)00150-O](https://doi.org/10.1016/0006-8993(95)00150-O).
5

1 **Figures & legends**



2

3 **Fig. 1: Ncad-mRADA stably incorporates in mRADA supramolecular hydrogel**

4 A–D: Hydrogel formations of RADA and mRADA peptides injected into intact adult
 5 mouse brains. Under light microscopy, semi-thin brain sections embedded in resin show
 6 formation of RADA (A) and mRADA (B) hydrogels in the striatum 5 days after injection.
 7 A', A'', B' and B'' are higher magnification images of the boxed areas in A and B. Electron
 8 microscopy images of the RADA (C) and mRADA (D) hydrogels in the striatum. C' and
 9 D' show higher magnification images of the boxed areas in C and D.

1 E: The incorporation ratios of non-tagged EGFP and mRADA-tagged EGFP. Protein
2 incorporation (%) = [(weight of input) – (weight of the soluble fraction)] / (weight of
3 input) × 100 (%). $n=3$. Student's t-test.

4 F: The ratios of unreleased EGFP to incorporated EGFP. Unreleased protein /
5 incorporated protein (%) = [(weight of incorporated protein) – (total weight of the soluble
6 fraction)] / (weight of incorporated protein) × 100 (%). $n = 3$.


7 G: Scheme of Ncad-mRADA nanofiber production. A plasmid encoding mRADA
8 peptide attached to the N-cadherin extracellular domain sequence was constructed. 293T
9 cells were transfected with the Ncad-mRADA-expressing plasmid. Purified and
10 concentrated Ncad-mRADA proteins were incubated with mRADA. The crystal structure
11 of the mouse N-cadherin extracellular domain was obtained from PDB3Q2W.

12 H–I: Western blots for released Ncad-mRADA (H) and Ncad-Fc (I) after incubation for
13 144 h.

14 J: Experimental design using intact adult mice. Schematic image of a coronal brain
15 section shows material injection site (dotted pink line).

16 K: Immunological responses to the transplanted biomaterials. The RADA, mRADA, or
17 Ncad-mRADA self-assembling peptides were injected into the striatum of intact adult
18 mice, and brain sections were prepared 5 days later. The graph shows the percentage
19 microglial marker Iba1+ area within 300 μm from the transplanted materials, which was
20 not significantly different among these biomaterials. RADA, $n=8$; mRADA, $n=10$; Ncad-
21 mRADA, $n=7$. One-way ANOVA followed by Bonferroni post hoc test.

22 Graphs show the mean \pm SEM. $*p<0.05$. Scale bars: 200 μm , A and B; 50 μm , A', A'',
23 B' and B''; 2 μm , C and D; 0.5 μm , C' and D'.
24



1
2 **Fig. 2: Ncad-mRADA promotes neuroblast migration toward the injured area in the**
3 **adult brain**
4 A–B: Experimental design using a cerebral stroke model. Schematic image of a coronal
5 brain section after middle cerebral artery occlusion (MCAO) shows locations of the
6 infarct area (brown area), the V-SVZ (green line) and the injection site (dotted pink line)
7 (A). Timeline of the experimental procedures is shown in (B).
8 C–F: Distribution of neuroblasts in the brain after stroke followed by PBS, mRADA or
9 Ncad-mRADA injection. Z-stack projection images of the mRADA injection sites in the
10 striatum from coronal brain sections immunostained for neuroblast marker Dcx (C–D

1 green). mRADA and Ncad-mRADA hydrogels were visualized with AlexaFluor 647-
2 conjugated azide (Alexa647-azide, magenta). Nuclei were labeled with Hoechst 33342.
3 C' and D' are single-plane higher magnification images of the boxed areas in C and D,
4 respectively. C'' and D'' show cross-section images of the areas indicated in C' and D'
5 (white dotted lines), respectively. The graphs show the numbers of Dcx+ neuroblasts in
6 the V-SVZ (E, per section), and those in areas of post-stroke striatum at different
7 distances (100 to <200 μm , 200 to <300 μm , 300 to <500 μm , and ≥ 500 μm) from the V-
8 SVZ (F, per mouse). The neuroblasts <100 μm (bottom), 100 to <200 μm (middle) and
9 200 to <300 μm (top) from PBS, $n=8$; mRADA, $n=14$; Ncad-mRADA, $n=9$) injection
10 sites were separately counted. One-way ANOVA followed by Bonferroni post hoc test.
11 (E) and Wilcoxon rank sum test (F).


12 G–H: Quantification of distributed non-neuronal cells in the vicinity of mRADA or Ncad-
13 mRADA injection sites. The graphs show percentages of astrocyte marker GFAP+ area
14 within 100 μm from mRADA ($n=12$) or Ncad-mRADA ($n=7$) injection sites (G) and
15 quantification of total endothelial cell marker CD31+vascular length per area analyzed
16 within 100 μm from mRADA ($n=5$) or Ncad-mRADA ($n=4$) injection sites (H).
17 Student's t-test (G and H).

18 I–N: Single-plane images of the injection sites in the striatum of coronal brain sections
19 immunostained for GFAP (I and J, white), CD31 (K and L, green) and microglial marker
20 Iba1 (M and N, green). Blood vessels are indicated by white arrowheads.

21 O–P: Experimental design of the cortical injury model. Schematic image of a coronal
22 brain section after cryogenic injury shows locations of the lesion site (brown area), the
23 V-SVZ (green line) and the material injection site (dotted pink line) (O). Timeline of the
24 experimental procedures is shown in (P).


25 Q–T: Distribution of neuroblasts in the brain after cortical injury and biomaterial injection.
26 Z-stack projection images of the mRADA injection sites in the cortex from coronal brain
27 sections immunostained for neuroblast marker Dcx (green) at five days after material
28 injection (Q–R). mRADA and Ncad-mRADA hydrogels were visualized with AlexaFluor
29 647-conjugated azide (Alexa647-azide, magenta). R'-R'' are higher magnification
30 images of the boxed areas in R. The graphs show the numbers of Dcx+ neuroblasts in the
31 V-SVZ (S, per section), and those in areas of injured cortex at different distances (200 to
32 <300 μm , 300 to <500 μm , and ≥ 500 μm) from the V-SVZ (T, per mouse). The
33 neuroblasts <100 μm (bottom), 100 to <200 μm (middle) and 200 to <300 μm (top) from
34 mRADA, $n=4$; Ncad-mRADA, $n=5$) injection sites were separately counted. Student's t
35 test (S and T, 300 to <500 μm , ≥ 500 μm) and Wilcoxon rank sum test (T, 200 to <300
36 μm).

1 Graphs show the mean \pm SEM. * p <0.05, ** p <0.01. Scale bars: 100 μ m, Q–R; 40 μ m, C–
 2 D; 30 μ m, R'–R''; 20 μ m, C'–D' and I–N; 10 μ m, C''–D''.



3

1 **Fig. 3: Ncad-mRADA enhances neuroblast migration towards injured neocortex**
2 A–E: Migration profiles of neuroblasts in contact with the biomaterials. Light microscopy
3 images of neuroblasts migrating on an mRADA or Ncad-mRADA hydrogel-coated dish
4 at different time-points (A). The graphs show quantitative data of migrating speed (B),
5 distance of stride (C), duration of migrating cycle (D), and duration of resting period (E)
6 of neuroblasts on dishes coated with mRADA hydrogel, Ncad-mRADA hydrogel or
7 mRADA hydrogel mixed with Fc domain-conjugated N-cadherin extracellular domain
8 (Ncad hydrogel). At least two independent cultures prepared on different days were used
9 for the analyses. Data are the mean \pm SEM. $n=9-10$ cells each. Kruskal-Wallis test with
10 Steel-Dwass test.
11 F–G: Distribution of neuroblasts in hydrogels formed in the injured neocortex. Z-stack
12 projection image of Dcx+ neuroblasts (green) distributed inside the mRADA hydrogel,
13 Ncad-mRADA hydrogel or mRADA hydrogel mixed with Ncad-Fc (Ncad hydrogel) four
14 days after injection (F). The mRADA hydrogels were visualized with Alexa647-
15 conjugated azide (Alexa647-azide, magenta). The graph shows the density of Dcx+
16 neuroblasts inside these mRADA hydrogels (G). Data are represented as box and whisker
17 plots with individual data points. mRADA, $n=14$; Ncad-mRADA, $n=7$; Ncad, $n=9$.
18 Kruskal-Wallis test with Steel-Dwass test.
19 H–I: Distribution of neuroblasts in neocortex layers after injury. Schematic image shows
20 coronal brain sections with cortical injury (gray) and the injection site (dotted pink line)
21 (H). Magnified schematic diagram of the boxed area in (H) describes neuroblasts (green)
22 migrating from the V-SVZ toward the injured neocortical layers (lower, middle and
23 upper) in the hydrogel (magenta) (H'). The graph shows the density of Dcx+ neuroblasts
24 in the dorsal V-SVZ, corpus callosum (CC), and neocortical layers (lower, middle and
25 upper, indicated in H') at four days after injection of mRADA or Ncad-mRADA (I). Data
26 are the mean + SEM with individual data points. $n=4$, each. Students' t-test.
27 * $p<0.05$, ** $p<0.01$, *** $p<0.001$. Scale bars: 10 μm , A; 50 μm , F.




1

1 **Fig. 4: Spatial interactions between neuroblasts and Ncad-mRADA fibers**

2 Transmission electron microscopy of the neonatal neocortex after cryogenic injury and
3 Ncad-mRADA hydrogel injection (A–H). In low magnification images, (A, B, F, G),
4 neuroblasts (Nb) identified by their smooth and elongated cell bodies, small elongated
5 nucleus with lax chromatin and scant cytoplasm containing many free ribosomes and
6 microtubules are colored green. Injury activated microglia (Mg), identified by clumped
7 chromatin in nuclei and many vacuoles and lysosomes in the cytoplasm, are colored
8 purple, and Ncad-mRADA hydrogel is colored pink (B, G). The cluster of neuroblasts
9 directly contact Ncad-mRADA (A, B). Higher magnification images of the boxed areas
10 in B show plasma membrane contact of three neuroblasts (C), adherens-junction like
11 contact (green arrowheads) and free spaces between neuroblasts (D), and direct contact
12 between a neuroblast and Ncad-mRADA fibers (E). Electron micrographs of individual
13 neuroblasts in an Ncad-mRADA hydrogel aggregate show extensive direct contact
14 between neuroblasts and the Ncad-mRADA fibers. G and H are higher magnification
15 images of boxed areas in F and G, respectively.

16 Scale bars: 5 μm , A, F; 1 μm , B, G; 0.2 μm , C–E, H.

17



1

2 **Fig. 5: Ncad-mRADA promotes neuronal regeneration and improves sensorimotor**
 3 **functions during postnatal development**


4 A: Experimental design for labeling V-SVZ-derived cells for histological analyses and
 5 neurological assessments.

6 B–C: Z-stack projection images of coronal brain sections show that EmGFP-labeled
 7 (green) V-SVZ-derived cells in the vicinity of the injury express mature neuronal marker
 8 NeuN (red). While NeuN+EmGFP+ V-SVZ-derived mature neurons are restricted to the
 9 lower layer of the neocortex with mRADA hydrogel, they are distributed more widely

1 throughout the cortical layers with Ncad-mRADA hydrogel (B). Magnified view of the
2 EmGFP+NeuN+ cells in the boxed areas are presented in C (arrows).
3 D-F: Single plane image of coronal brain sections show that EmGFP-labeled (green) V-
4 SVZ-derived cell in the injured cortex expresses MAP2 (red) on the soma and a neurite
5 (D). Z-stack projection image of coronal sections show that some V-SVZ-derived cells
6 (green) in the injured cortex express GAD67 (red) (E). Another single plane image
7 indicates the Gephyrin (red) expression on the EmGFP-labelled small protrusions (F).
8 G: Proportion of EmGFP+NeuN+ cells distributed in the upper layer of the neocortex in
9 mRADA ($n=9$) and Ncad-mRADA ($n=10$) groups. Data are the mean + SEM. Welch's t
10 test.
11 H: Neurological assessments of P29 mice with or without brain injury and a self-
12 assembling peptide injection. The graph represents the percentage of mis-steps (% error)
13 in the foot-fault test. Intact, $n=27$; injury, $n=33$; injury followed by mRADA hydrogel
14 treatment (mRADA), $n=20$; injury followed by Ncad-mRADA hydrogel treatment
15 (Ncad-mRADA), $n=18$. Data are represented as box and whisker plots with individual
16 data points. One-way ANOVA with Benjamini, Krieger, and Yekutieli FDR test.
17 I-J: Gait analysis at P33±2. The graph represents "Max contact area" of left forelimb (I)
18 and left hindlimb (J). Intact, $n=18$; injury, $n=13$; injury followed by mRADA hydrogel
19 treatment (mRADA), $n=10$; injury followed by Ncad-mRADA hydrogel treatment
20 (Ncad-mRADA), $n=13$. Data are represented as box and whisker plots with individual
21 data points. One-way ANOVA with Benjamini, Krieger, and Yekutieli FDR test.
22 K: Experimental design using *NSE-DTA* mice.
23 L: Quantification of immunostained EmGFP-labeled V-SVZ-derived cells in the injured
24 cortex expressing NeuN in *NSE-DTA* mice (*NSE-DTA*, $n=5$) or wild-type mice (WT,
25 $n=5$) treated with Cre recombinase followed by cryoinjury and Ncad-mRADA injection.
26 Data are the mean + SEM. Students t-test.
27 M: Foot-fault test of P29 mice with electroporation, viral induction and cryogenic injury
28 followed by Ncad-mRADA injection. *NSE-DTA*, $n=9$; WT, $n=12$. Data are represented
29 as box and whisker plots with individual data points. Students' t-test.
30 * $p<0.05$, *** $p<0.001$, # $q<0.05$, ## $q<0.001$. Scale bars: 50 μm , B; 20 μm , C; 10 μm , D, E;
31 1 μm , F.

32

1 Supplementary Information




2

3 **Supplementary Figure 1: Characterization of EGFP-mRADA, Ncad-RADA, and** 4 **Ncad-mRADA and Rheology of mRADA incorporating Ncad-mRADA**

5 A: Western blotting of EGFP-mRADA (left) and Ncad-RADA and Ncad-mRADA (right).
6 80 μ g of EGFP-mRADA and 80 ng of Ncad-RADA and Ncad-mRADA proteins were
7 mixed with SDS loading buffer and subjected to SDS-PAGE on 12% polyacrylamide gels.
8 The proteins were then electroblotted onto polyvinylidene fluoride membranes using an
9 iBlot Gel Transfer Device (Thermo Fisher Scientific). The membranes were incubated
10 with rabbit anti-GFP (1:5,000, ab290, Abcam) and rabbit anti-N-cadherin (1:5,000,
11 ab76011, Abcam) for 16 h at 4°C after blocking with 5% skim milk for 1 h at room
12 temperature, and then with peroxidase-labeled goat anti-rabbit IgG (1:5,000, Dako,
13 Glostrup, Denmark) for 2 h. The bands were detected using SuperSignal West Femto
14 Maximum Sensitivity Substrate (Thermo Fisher Scientific) and were visualized using a
15 Amersham ImageQuant 800 (Cytiva; Tokyo, Japan).

16 B-C: Strain-dependent storage (G' , red) and loss (G'' , blue) moduli profiles of mRADA
17 (B) and a mixture of mRADA and Ncad-mRADA (C) in PBS buffer at 25°C (mRADA
18 concentration: 0.5 wt%, Ncad-mRADA concentration: 40 ng/ μ L, pH 3.0).

19



1

2 **Supplementary Figure 2: Ncad-mRADA injected into the striatum of intact mice**
 3 **contacts more neuroblasts than other materials**


4 A: Schematic image of a coronal brain section shows the V-SVZ (green line) and the
 5 injection site (dotted pink line).

6 B: Distribution of neuroblasts in the intact brain at five days after RADA, mRADA and
 7 Ncad-mRADA injection. Single-plane images of the injection site in the striatum from
 8 coronal brain sections immunostained for neuroblast marker Dcx (green). RADA,
 9 mRADA and Ncad-mRADA hydrogels were visualized with AlexaFluor 647-conjugated
 10 azide (Alexa647-azide, magenta).

11 C: The graph shows the numbers of Dcx+ neuroblasts in the areas of the striatum at
 12 different distances from injection sites (<100 μm and 100 to <300 μm) from RADA ($n=6$),
 13 mRADA ($n=11$) or Ncad-mRADA ($n=7$) injection sites (per mouse). Kruskal-Wallis test
 14 followed by Steel-Dwass test. Graphs show the mean \pm SEM.

15 * $p<0.05$, ** $p<0.01$. Scale bars: 20 μm, B.

16



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Supplementary Figure 3: Ncad-mRADA increases the number of V-SVZ-derived mature neurons in the post-stroke striatum

A: Experimental design for analyzing maturation of V-SVZ-derived cells in the post-stroke striatum using Nes-CreER;R26R-ECFP transgenic mice.


B-C: Representative images of ECFP-labeled (GFP+, green) cells (white arrows) expressing NeuN (red), but not Dcx (white) around the injection tracks (white dotted lines) of mRADA (B) and Ncad-mRADA (C) at 56 days after MCAO.

D: Quantification of the number of GFP+NeuN+Dcx- cells in the post-stroke striatum within 200 μm from the needle tracks. The number was significantly higher in the Ncad-mRADA group (n=5) compared with the mRADA group (n=6). Student's t test.

E-G: Foot-fault test at 12 days (E), 28 days(F), and 55 days(G) after stroke induction (MCAO). stroke followed by mRADA hydrogel treatment (mRADA), n=5; injury followed by Ncad-mRADA hydrogel treatment (Ncad-mRADA), n=6. Data are represented as box and whisker plots with individual data points. Student's t test.

Graphs show the mean ± SEM. *p<0.05. scale bars: 50μm

1



2

3 **Supplementary Figure 4: Ncad-mRADA does not affect immune cell infiltration in** 4 **the post-stroke striatum**

5

6 A: Representative images of infiltrated blood cells around the mRADA hydrogel in the
7 post-stroke brain. The brain sections 18 days after MCAO were immunostained for
8 general leukocyte CD45 (green) and macrophage/microglial marker for Iba1 (white). The
9 mRADA hydrogel was visualized with AlexaFluor 647-conjugated azide (Alexa647-
10 azide, magenta). White arrowheads and arrows indicate leukocytes that express CD45 at
11 high level (CD45^{high}) with and without expressing Iba1, respectively.

12 B-C: Quantification of leukocytes infiltrated around the mRADA and Ncad-mRADA
13 hydrogels. The graphs show the density of CD45^{high}Iba1⁺ cells (macrophages, B) and
14 CD45^{high}Iba1⁻ cells (subtypes of leukocytes other than macrophages, C) in the striatum
15 within 300µm from the injection track of mRADA (*n*=4) or Ncad-mRADA (*n*=4). There
16 were no significant differences in both of the cell densities between the groups. Student's
17 t test. Graphs show the mean ± SEM.


18

19

20

21

22




Supplementary Figure 5: N-cadherin containing mRADA peptides promote migration of GFP-labeled neuroblasts derived from Dcx-EGFP mouse V-SVZ

A: Representative image of the day 3 **in vitro** V-SVZ culture using Dcx-EGFP mice. Dcx-EGFP+ (green) cells were immunostained for Dcx (red) and GFP (green) and counter stained with Hoechst33342 (blue).

B: Quantitative analysis of the Dcx-EGFP+ cells from the day 3 *in vitro* V-SVZ culture shown in percentage. Graph shows the mean \pm SEM.

C-D: DIC and Green fluorescence images of migrating Dcx-EGFP+ cells on an mRADA or Ncad-mRADA hydrogel-coated dish at different time-points (C). The graph shows quantitative data of migrating speed of neuroblasts on dishes coated with mRADA hydrogel, Ncad-mRADA hydrogel or mRADA hydrogel mixed with Fc domain-conjugated N-cadherin extracellular domain (Ncad hydrogel, Ncad) (D). At least two independent cultures prepared on different days were used for the analyses. Data are the mean \pm SEM. mRADA, $n=25$; Ncad-mRADA, $n=27$; Ncad, $n=24$ cells each. One-way ANOVA followed by Bonferroni post hoc test. $**p<0.01$. Scale bar: 50 μm , A.



1

2 **Supplementary Figure 6: Ncad-mRADA peptide treatment promotes sensorimotor**
 3 **recovery in mice after neonatal cortical injury**

4 A-B: Coronal brain sections of wild-type mice after electroporation of *EmGFP*-encoding
 5 plasmid at P0, neocortical injury at P2 and Ncad-mRADA injection at P5, and fixation at
 6 P9 were immunostained for Dcx and NeuN. The EmGFP-labeled V-SVZ-derived cell
 7 (green) are distributed in the injured tissue where NeuN⁺ mature neurons (white) are lost
 8 (A). A high magnification image of boxed area in (A) shows EmGFP-labeled cell (green)
 9 in injured cortex expressing Dcx (red), but not NeuN (white) (B).

10 C-D: Elevated body swing test (EBST) on P30 mice with or without brain injury and a
 11 self-assembling peptide injection. The graph represents the percentage of right swings (%
 12 Swing to the right) in the EBST (C). The absolute differences of the percentage of right
 13 swing in each mouse from that of the average value in intact group was quantified and
 14 plotted (D). Intact, $n=13$; injury, $n=13$; injury followed by mRADA hydrogel treatment
 15 (mRADA), $n=11$; injury followed by Ncad-mRADA hydrogel treatment (Ncad-mRADA),
 16 $n=15$. Data are represented as box and whisker plots (C) and as violin plots (D) with
 17 individual data points. One-way ANOVA with Benjamini, Krieger, and Yekutieli FDR
 18 test.

19 E: Foot-fault test on P31 mice with or without RADA injection after cryogenic injury.
 20 Injury, $n=10$; RADA, $n=10$. Students' t-test.

21 $ns \geq 0.05$, $\# q < 0.05$, $\#\# q < 0.001$. Scale bars: 100 μm , A; 10 μm , B.

1 **Supplementary Movie 1: Time-lapse imaging of cultured neuroblasts migrating on**
2 **mRADA and Ncad-mRADA hydrogels**

3 The behavior of migrating neuroblasts was recorded at 1-min intervals. Sequential images
4 of these neuroblasts are shown in Figure 3A.

5

6

1 **Materials and Methods for Supplementary Data**

2
3 **Ncad-mRADA injected into the striatum of intact mice contacts more neuroblasts**
4 **than other materials**

5 Eight-to-ten-week-old male mice were anesthetized and subjected to the
6 following procedures. Prior to injection of the synthesized peptide solution, scalp and
7 parietal bone near the injection sites were resected to expose the brain. Peptide solution
8 (2.5 μ l) was injected into the intact medial striatum (1.55 mm anterior, 0.8 mm lateral to
9 bregma, 1.50–3.0 mm deep).

10 The mice were transcardially perfused 5 days after the material injection with
11 phosphate buffered saline (PBS, pH 7.4), followed by 4% paraformaldehyde (PFA) in 0.1
12 M phosphate buffer (PB, pH 7.4). Tissues were further fixed in the same fixative
13 overnight. Coronal sections 50 μ m thick were then prepared with a vibratome VT1200S
14 (Leica, Wetzlar, Germany). The sections were immunostained for Dcx and injected
15 material was visualized with AlexaFluor 647-conjugated azide.

16 Images were acquired using an LSM700 confocal microscope equipped with
17 10 \times /0.45 and 20 \times /0.8 objective lenses. Samples with material injection within 200 μ m of
18 the V-SVZ were selected and subjected to quantitative analysis. The number of
19 neuroblasts in every third 50- μ m-thick coronal section was counted and the neuroblast
20 number was multiplied by three to obtain the total number of cells per animal. The
21 neuroblasts that were closer than 100 μ m or 100 to <300 μ m from the injection site were
22 analyzed. The area within 100 μ m from the V-SVZ was excluded from counting. Mice
23 with RADA ($n=6$), mRADA ($n=11$) and Ncad-mRADA ($n=7$) hydrogels were analyzed
24 (Fig. S2).

25
26 **Maturation of V-SVZ-derived cells in the post-stroke brain of adult mice**

27 Male adult Nestin-CreER;R26R-ECFP mice obtained by crossing the Nestin-
28 CreER mice [43] and R26R-ECFP transgenic mice [63] described previously were used.
29 Tamoxifen administration induces nuclear transfer of Cre recombinase in nestin promoter
30 active neural stem/progenitor cells, which results in removal of a “floxed” STOP
31 sequence at the Rosa 26 locus, leading to persistent expression of a fluorescent protein
32 ECFP. The mice were injected with tamoxifen (100 mg/kg/day) at three and one days
33 before MCAO operation, then injected with Ncad-mRADA or mRADA at day 13, and
34 fixed at day 56 days after MCAO. The coronal brain sections were immunostained with
35 GFP (rabbit anti-GFP (1:500, MBL, Tokyo, Japan)), Dcx (guinea-pig anti-DCX (1:800,
36 Millipore)) and NeuN (mouse anti-NeuN (1:200, Millipore)) antibodies. Images of the
37 areas with needle tracks of biomaterial injection in the ipsilateral striatum were obtained

1 using confocal laser microscope (FV3000, Olympus). The number of ECFP-labeled
2 (GFP+) cells expressing NeuN, but not Dcx distributed within 200 μm from the needle
3 tracks were counted (Fig. S3).

4 5 **Foot-fault test on the post-stroke adult mice**

6 The foot-fault test on adult mice was performed as previously described with
7 modifications [37]. Briefly, mice were placed on elevated hexagonal grids of 40-mm
8 diameter. The mice placed their paws on the wire and moved along the grid. With each
9 weight-bearing step, the paw may fall or slip between the wire; either type of misstep was
10 recorded as a foot-fault. The number of foot-faults for each limb was separately counted
11 for 6 min, and then the percentages of foot faults were calculated as follows. The trials
12 were repeated at 12 days (one day before biomaterial injection), 28 days, and 55 days
13 after stroke induction (MCAO). The mice were trained to walk on the grid for 20 min the
14 day before the trial. The number of left hindlimb foot-faults was divided by the number
15 of the total foot-faults of left and right hindlimb and described in percentage (Fig. S3).

16 17 **Immunohistochemistry**

18 To examine immune cell infiltration in the brain after biomaterial injection, 18
19 day-post-stroke brain sections injected with Ncad-mRADA or mRADA were
20 immunostained for general leukocyte marker, CD45 (rat anti-CD45 (1:400, Bio-Rad,
21 California, USA)) and macrophage/microglial marker Iba1 (rabbit anti-Iba1 (1:2,000,
22 Wako Pure Chemical Industries, Osaka, Japan)). The hydrogels were visualized with
23 AlexaFluor 647-conjugated azide. Cells expressing CD45 at high level (CD45^{high}) were
24 regarded as leukocytes. Using the images of the areas around the hydrogels obtained using
25 confocal laser microscope (FV3000, Evident), the density of CD45^{high} Iba1⁺ cells
26 (macrophages) and CD45^{high} Iba1⁻ cells (subtypes of leukocytes other than macrophages)
27 were quantified (Fig. S4).

28 29 **V-SVZ neuroblast culture from *Dcx-EGFP* mice**

30 Glass-bottom 35-mm Petri dishes coated with mRADA, Ncad-mRADA or Ncad
31 hydrogel were prepared prior to cell preparation. The dishes were incubated with the
32 biomaterial solution for 30 min at 4°C and for a further 30 min at 37°C. The dishes were
33 rinsed once with PBS and air-dried in a laminar flow hood until use. V-SVZ tissues were
34 dissected from postnatal day 0 *Dcx-EGFP* mice [28] and dissociated with trypsin-EDTA
35 (Thermo Fisher Scientific). The cells were washed with L-15 medium (Thermo Fisher
36 Scientific) containing 20 $\mu\text{g}/\text{ml}$ DNaseI (Roche). The cell aggregate was embedded in
37 50% Matrigel (BD Biosciences, diluted in Hank's balanced salt solution (Thermo Fisher

1 Scientific). The cells were cultured in Neurobasal medium containing 2% B-27%
2 supplement, 2 mM L-glutamine and 50 U/ml penicillin-streptomycin at 37°C with 5%
3 CO₂ for 48 h before imaging. Details of the cell preparation is described elsewhere [33].
4 Time-lapse video recordings were performed using a BZ-X800 fluorescence microscope
5 (Keyence, Osaka, Japan) equipped with a ×20 dry objective lens. Both DIC and green
6 fluorescence images of *Dcx-EGFP*⁺ cells were obtained every 4 min for 24 h under
7 humidified conditions at 37°C with 5% CO₂. The migrating *Dcx-EGFP*⁺ cells were
8 analyzed using a manual tracking plugin of the ImageJ software (National Institutes of
9 Health, Bethesda, MD, USA).

10 After the time-lapse imaging, the cells were fixed with 4% PFA in PB. The fixed
11 cells were further proceeded with immunostaining. Briefly, the cells were permeabilized
12 and blocked with blocking buffer (10 % normal donkey serum, 0.4% Triton-X100 in PBS)
13 for 1 h and incubated with primary antibody solution containing rat anti-GFP (1:500,
14 Nacalai, Kyoto, Japan) and rabbit anti-DCX (1:500, Cell Signaling Technologies)
15 antibodies in the blocking buffer overnight at 4°C. Then the cells were washed and stained
16 with anti-rat AlexaFluor488 and anti-rabbit AlexaFluor568 antibodies (1:1,000, Thermo
17 Fisher Scientific) in blocking buffer for 1 h. Cell nuclei were stained with Hoechst 33342
18 stain (1:5,000, Invitrogen). Images were acquired using an LSM700 confocal microscope
19 equipped with 20×/0.8 objective lens. Images from 5 individual V-SVZ aggregates were
20 obtained and percentage of GFP⁺ cells/ total Hoechst⁺ cells was quantified (Fig. S5).

21 22 **Postnatal V-SVZ labeled cells analysis**

23 To label V-SVZ cells 2 μl plasmid solution (4 μg/ml *pCAGGS-EmGFP* [35] in
24 distilled water containing 0.01% Fast Green) was injected into the lateral ventricle of the
25 right hemisphere of P0 ICR mice using the following stereotaxic coordinates: 2.0 mm
26 anterior, 1.2 mm lateral to lambda and 2.0 mm deep. The animals were subjected to three
27 electrical pulses (70 V, 20.0 msec) using a Super Electroporator NEPA21 Type II (Nepa
28 Gene, Chiba, Japan) and 10 mm tweezer electrodes (CUY650P10, Nepa Gene, Chiba,
29 Japan). Electroporated animals were placed on a heating plate before being returned to
30 their home cage. Next, the electroplated P2 animals were subjected to cryogenic injury.
31 Briefly, a pre-chilled 1.2 mm-wide hexagonal wrench was prepared in liquid nitrogen and
32 was placed on the exposed right skull (0.5-mm anterior and 1.2-mm lateral to lambda) for
33 10 seconds. The procedure was repeated three times with a time interval of 5 seconds to
34 re-chill the probe. Then P5 animals were subjected to intracortical injection of 2 μl Ncad-
35 mRADA solution into the lesion site (1.0–1.5 mm deep from the skull surface). After the
36 injection, the capillary needle was kept in the injection site for 5–7 min, until hydrogel
37 formation was accomplished. Mice were transcardially perfused 5 days after the injection

1 with PBS (pH 7.4), followed by 4% paraformaldehyde (PFA) in 0.1 M PB (pH 7.4).
2 Tissues were further fixed in the same fixative overnight. The obtained brain sections
3 were immunostained overnight at 4°C with the primary antibodies of rat anti-GFP (1:500,
4 Nacalai, Kyoto, Japan), guinea pig anti-DCX (1:800, Millipore) and rabbit anti-NeuN
5 (1:1000, Abcam), followed by secondary antibody solution containing AlexaFluor-
6 conjugated secondary antibodies (1:1,000, Thermo Fisher Scientific) for 2 h at room
7 temperature. Cell nuclei were stained with Hoechst 33342 stain (1:5,000, Invitrogen).
8 Images were acquired using an LSM700 confocal microscope equipped with 20×/0.8
9 objective lens (Fig. S6).

11 **Elevated body swing test**

12 To analyze the asymmetric motor behavior [17,64] in mice after neonatal cortical
13 injury, P30 wild-type mice after cryogenic injury at P2 with or without following
14 mRADA or Ncad-mRADA peptide injection at P5, or intact mice were subjected to the
15 elevated body swing test (EBST). The mice were acclimated in the procedure room for
16 20 min before the test. The tail was taken ca. 4 cm from the base and was suspended
17 approximately 10 cm above the table for 90 seconds in the vertical axis. Swings to the
18 left or right was counted when the animal moved its head out of the vertical axis at least
19 90°. Swings were recorded with the video camera, and the percentage of right swings was
20 determined. The absolute difference between average value of the intact mice and each
21 value was shown in the violin plots (median and first and third quartiles for each group
22 data are shown) (Fig. S6).

24 **Foot-fault test on neonatal cryoinjured mice with or without RADA injection**

25 The foot-fault test was performed as previously described with modifications
26 [37] on cryoinjured P31 ICR mice with or without RADA injection. Briefly, mice roamed
27 on 20-cm elevated hexagonal wire grids with 40-mm diameter openings for 10 min on a
28 day prior to the test. During the test, each mouse was tested for 5 min on the grid and the
29 total number of steps and foot-faults for the left hindlimb were recorded. A misplaced
30 limb that slipped on the grid or fell through the openings in the grid was counted as a
31 foot-fault. The number of foot-faults for the left hindlimb was divided by the total number
32 of hindlimb steps to determine percentage of the fault steps. The test was repeated twice
33 on the same day for each mouse and the percentage of the fault steps averaged (Fig. S6).

35 **Time-lapse imaging of cultured neuroblasts migrating on mRADA and Ncad- 36 mRADA hydrogels**

1 Glass-bottom 35-mm Petri dishes coated with mRADA or Ncad-mRADA
2 hydrogel were prepared prior to cell preparation. The dishes were incubated with the
3 biomaterial solution for 30 min at 4°C and for a further 30 min at 37°C. The dishes were
4 rinsed once with PBS and air-dried in a laminar flow hood until use.

5 V-SVZ tissues were dissected from postnatal day 0 ICR mice and dissociated
6 with trypsin-EDTA (Thermo Fisher Scientific). The cells were washed with L-15 medium
7 (Thermo Fisher Scientific) containing 20 µg/ml DNaseI (Roche). The cell aggregate was
8 embedded in 50% Matrigel (BD Biosciences, diluted in Hank's balanced salt solution
9 (Thermo Fisher Scientific). The cells were cultured in Neurobasal medium containing 2%
10 B-27% supplement, 2 mM L-glutamine and 50 U/ml penicillin-streptomycin at 37°C with
11 5% CO₂ for 48 h before imaging. Details of the cell preparation is described elsewhere
12 [33]. Time-lapse video recordings were performed using a BZ-X800 fluorescence
13 microscope (Keyence, Osaka, Japan) equipped with a ×20 dry objective lens. Images of
14 neuroblasts were obtained every 1 min for 24 h under humidified conditions at 37°C with
15 5% CO₂ (Movie S1).